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6Preface 
“Smile – things may get worse more slowly.” Unknown
Life is multivariate and full of coincidences. This story started in Finland at the 
Helsinki University of Technology. I wanted to become an architect but I became a 
chemical engineer specialized in bioprocess engineering and food technology – since 
all “bio” stuff was considered to ensure a great future (and work) in the beginning of 
the 1990’s. Instead of working, I continued with post graduate studies. I spent long 
sleepless nights beside a bioreactor with bacteria producing a valuable enzyme. I 
collected lot of samples, analyzed them and produced many sheets full of numbers. At 
some point I had to give my data to somebody who was “just” sitting, playing around 
with neural networks and working from nine to five. I was so bitter. 
After two-three years of frustration and struggling with ill-behaving bacteria Heikki 
Haario mentioned the word “chemometrics” and gave an introduction to experimental 
design and modelling at the graduate school course on “Mathematical Tools in 
Biosciences”. I began to see the light and managed to talk myself into the Umetrics 
courses “Design of Experiments” and “Multivariate Data Analysis” given by Veli-
Matti Taavitsainen and Håkan Fridén. The feeling was almost schizophrenic – I was 
angry because nobody had taught this to us at the university and happy because, now, 
I (thought I) knew what to do. I would design a series of controlled experiments and 
optimize my enzyme production and I would use multivariate analysis for modelling 
and prediction. Unfortunately the reality stroke back: “We don’t use these methods 
here” was the answer I got.  
But I was converted and there was no way back to the old way of thinking. So when 
my friend Terhi Siimes asked me to join her at a software company representing 
Umetrics and its chemometrics software in Finland, I literally “left the building”. No 
more wet chemistry for me – just data, please. I learned to know the “old” gentlemen 
from Umetrics (Håkan, Erik Johansson, Christer Albano, Conny Wikström, and 
7Lennart Eriksson) and started to give courses myself. I enjoyed teaching and 
spreading the message but I also realized that multivariate thinking was not as 
obvious to everybody as I had expected.  
Through Umetrics I came in contact with Professors Svante Wold and Michael 
Sjöström in Umeå (Sweden). Michael arranged me a grant for post graduate studies at 
Umeå University; for me it was a fantastic opportunity to become a real 
chemometrician. I packed my things and moved from Helsinki to Umeå in February 
2000. I worked with protein sequence data and bioinformatics. Yet another hot and 
promising “bio” stuff. I guess I was an outlier in a gang of Ume chemometricians and 
organic chemists since I didn’t quite understood the Swedish way of doing things and 
the famous Jante law (though back in Finland they said that I’d been “swedished”).   
In August 2001 at the 7th Scandinavian Symposium on Chemometrics (SSC7) in 
Copenhagen I met a very special guy from Bergen. His name was Olav Martin 
Kvalheim and he turned my life upside down. After a few months travelling between 
Sweden and Norway I decided to pack my things again and move to Norway in June 
2002. I continued my studies but at the same time I started my own one-woman 
company giving courses and consulting in chemometrics, especially in Finland.  
This PhD project started literally “by accident”. Olav got a neck problem during the 
spring 2003 and consulted a medical doctor. He was Christian Vedeler, professor in 
neurology at the Haukeland University Hospital. Olav got a prolapsed disc diagnosed 
but at the same time he managed to catch Christian’s interest on one of his research 
areas; the use of multivariate methods in spectral profiling and medical diagnosis. 
Christian arranged a meeting with Kjell-Morten Myhr, the leader of the Norwegian 
Multiple Sclerosis National Competence Centre. He understood the potentiality and 
happened to have interesting spinal fluid samples in a freezer. Rune Ulvik, professor 
in internal medicine, had already earlier started to collaborate with Olav, so we 
decided to start a project with Rune as a coordinator. New co-workers came and went 
and the project stayed alive mainly on a hobby basis. Different methods were tested 
and preliminary studies were carried out. Finally, I got funding from the Norwegian 
8Foundation for Health and Rehabilitation and started as a PhD student in April 2006 
after first giving a birth to the most important project of my life, Martin.      
All the persons mentioned above are acknowledged for their contribution to this story. 
The following persons earn an extra mentioning: 
Michael Sjöström gave me a chance to enter the chemometrics research community. 
He is not only a rewarded chemometrian but an extremely generous person and a 
beekeeper as well. 
Kjell-Morten Myhr and Christian Vedeler have been open-minded, extremely flexible 
and always very positive supervisors. 
Reidar Arneberg has programmed everything. He has calmly listened to my frustrated 
complaints and offered unconditional help. 
Magnus Berle has collected CSF samples from healthy controls. Frode Berven and 
Ann Cathrine Kroksveen have been responsible for the analytical workup and 
MALDI analyses. 
Olav Martin Kvalheim has offered me his solid competence, bursting creativity and 
lot of (conditional ) help. Privately, as a husband, even he shows tendency to 
univariate behaviour (Figure X). 
Figure X. System 
complexity. Thanks to a 
male course participant. 

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Abbreviations 
2DE  2-dimensional gel electrophoresis 
ANOVA Analysis of variance 
CCR  Correct classification rate 
CE  Capillary electrophoresis 
CIS  Clinical isolated syndrome 
CNS  Central nervous system 
COW  Correlation optimized warping 
CSF  Cerebrospinal fluid 
DA  Discriminant analysis 
DIVA  Discriminating variables 
DNA  Deoxyribonucleic acid 
DoE   Design of experiments 
ESI  Electrospray ionization 
HPLC  High performance liquid chromatography 
LV  Latent variable 
MALDI Matrix-assisted laser desorption/ionization 
MCCR Mean correct classification rate 
MLR  Multiple linear regression 
MRI  Magnetic resonance imaging 
MRM  Multiple reaction monitoring 
mRNA Messenger ribonucleic acid 
MS  Multiple sclerosis 
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MW  Molecular weight 
NHC  Neurological healthy controls 
OND  Other neurological diseases 
O-PLS Orthogonal PLS 
PC   Principal component 
PCA  Principal component analysis 
PLS  Partial least squares 
PLS-DA PLS-discriminant analysis 
PTM  Post-translational modification 
RAFFT Recursive alignment by fast Fourier transform
RNA  Ribonucleic acid 
ROC  Receiver operating characteristics 
SELDI Surface-enhanced laser desorption/ionization 
SR  Selectivity ratio 
TOF  Time-of-flight 
TP  Target projection 
VIP   Variable importance on projection 
Notations 
Generally, bold uppercase characters (e.g. X) represent matrices, bold lowercase 
characters (e.g. x) represent vectors, and italic characters (e.g. N) represent scalars. 
The transpose is indicated by a superscript T. Vectors are by default column vectors 
and transpose transforms them into row vectors. 
A   Number of LVs (PCA or PLS components) 
b  Regression coefficient vector 
11
Da  Dalton, unified atomic mass unit 
E  Residual matrix 
M   Number of objects/rows  
m/z  Mass-to-charge ratio 
N   Number of variables/columns  
nM  Nanomolar, 10-9 mol/L 
p  Loading vector 
P  Loadings matrix 
pM  Picomolar, 10-12 mol/L 
t  Score vector 
T  Scores matrix 
w  Weight vector 
X  Data matrix, spectral profiles  
y  Response vector 
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Abstract 
Mass spectrometry based protein profiling and biomarker discovery has given rise to 
the field of clinical proteomics. The underlying assumption is that proteins can 
provide information of diagnostic or therapeutic value and can thus be used in a 
clinical context. This thesis presents a novel approach where full mass spectral 
profiling and multivariate data analysis are combined to reveal biomarker signatures 
from complex body fluid samples. Matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry is employed for acquiring full spectral 
profiles of intact proteins in cerebrospinal fluid (CSF) proteome. Since MALDI-TOF 
is relatively straightforward to use and demands relatively simple analytical work-up, 
it may have the potential to be used on routine basis in clinical laboratories. Multiple 
sclerosis (MS) is used as a model disease to demonstrate how this approach works on 
real proteomics data. The aim is to detect a disease signature typical for MS and use it 
in disease classification. MS is an example of a disease that may be difficult to 
diagnose at its very early stage and there is a need for diagnostic biomarkers for early 
diagnosis and treatment. It should however be mentioned that the developed approach 
is general and can be applied for other diseases, body fluids and instrumental 
techniques as well. 
This thesis is composed of four scientific papers, each one focusing on a specific 
problem. In the first study (Paper I) different methods for pretreatment of spectral 
profiles are tested. The aim of this study is to obtain recipes for elimination of non-
compositional factors and thus improve reproducibility and minimize within-group 
variation compared to between-group variation. Statistical experimental design is 
used to assess the effect of each pretreatment step and examine if there are significant 
interactions between these steps. An optimal pretreatment strategy is developed and 
applied to further work. In the second and third study (Papers II and III) new 
chemometric methods are developed for detection of biomarker signatures in complex 
spectral profiles. In Paper II a so-called selectivity ratio (SR) and accompanying SR 
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plot are presented for the first time and validated using spiked CSF samples. In Paper 
III a non-parametric discriminating variable (DIVA) test is introduced. DIVA test can 
be used in combination with SR plot to define statistical boundaries for biomarker 
detection. Both methods are in fact general and can be applied for most kind of 
variable selection problems. In the fourth study (Paper IV) the novel multivariate 
approach (including data pretreatment, SR and DIVA) is applied to real proteomic 
data derived from CSF samples from three different patient groups (MS, other 
neurological diseases and neurological healthy controls). The presented approach is 
able to discriminate the groups and the most important mass spectral regions (i.e. m/z
values) contributing to separation can be found. These m/z values can be seen as a 
biomarker signature that can be used in disease classification. 
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1. Introduction 
“There is no adequate defence, except stupidity, against the impact of a new idea.” 
Percy Williams Bridgman  
A diagnosis is needed for starting any medical treatment. Once diagnosed with a 
certain medical condition, there may be many treatments available to help the patient. 
Early diagnosis and treatment will inevitably give the best prognosis for many 
diseases and also be cost-efficient for the society. Therefore more precise methods for 
early diagnosis are always needed. One way to achieve this goal is to search for 
disease specific markers. Biomarker discovery is currently playing a leading role in 
modern proteomics research. 
Mass spectral profiling of body fluids, for example, blood, urine, and cerebrospinal 
fluid (CSF), has become a common method when searching for biomarkers. Many 
proteins can be screened in a single experiment and, in principle, no biological 
knowledge about the disease is required to be able to accomplish the analysis. 
Discrimination between disease affected and healthy individuals is provided by the 
spectral pattern itself and no identification of the individual components is needed for 
separating different groups of patients. 
An important aspect in this context is data handling and analysis with subsequent 
feature selection and interpretation of the results. This is a challenging task because of 
the extreme complexity of the data (e.g. spectral profiles with many overlapping 
proteins). Traditionally, univariate statistics, like t-test, has been employed in data 
analysis. Unfortunately, use of univariate methods may lead to spurious results and 
false biomarkers. In addition, they cannot handle properly the situation with many 
variables contributing to the discriminatory pattern. Multivariate methods based on 
latent variables offer a better alternative since they take into account correlations in 
the data and provide tools for visualization of the data, detection of biomarker 
signatures and classification of samples. Furthermore, the multivariate methods are 
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not only applicable in the data analysis phase but also in the beginning of the study 
when planning and designing the experimental procedures. 
Partial least squares (PLS) regression is the workhorse in multivariate data analysis. 
The obtained results can, however, be difficult to interpret since multi-component 
PLS models are usually needed to describe the variation in complex spectral profiles. 
Methods like target projection (TP) and orthogonal PLS (O-PLS) circumvent this 
problem by finding a single linear combination of variables related to the response. 
Even though this makes interpretation easier one question remains: how to reveal the 
most important spectral variables that contribute to separation between different 
sample groups and thus may serve as biomarker signature. By introducing a new 
variable selection method called selectivity ratio (SR) and an accompanying non-
parametric statistical test called discriminating variable (DIVA) test, we are able to 
detect biomarker signatures from complex spectral profiles. 
1.1 The aims 
The main aim of this thesis was to develop general methods to reveal biomarker 
candidates in complex systems like body fluids using full mass spectral profiling and 
statistical multivariate data analysis. A secondary aim was to apply these methods on 
real proteomics data obtained from three groups of CSF samples, representing 
multiple sclerosis (MS), other neurological diseases (NHC), and neurological healthy 
controls (NHC), to detect the features distinguishing these groups.  
This thesis is based on following sub-studies, the results of which are published in 
four scientific papers: 
1. Pretreatment of mass spectral profiles. The aim in data pretreatment is to eliminate 
non-compositional features (e.g. baseline effects, shifts in m/z values, structured 
noise, and differences in absolute signal intensities due to amount of sample 
analyzed) from the mass spectral profiles without destroying the compositional 
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differences. This study shows how different data pretreatment steps influence 
spectral profiles obtained from matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry. Factorial experimental designs, with 
pretreatment steps as design variables and inter- to intragroup variation as a 
response variable, are used to make a quantitative assessment of the effects. 
Interpretation of the resulting empirical models makes it possible to propose 
optimal schemes for pretreatment of mass spectral profiles obtained from MALDI 
and related techniques. (Paper I)  
2. Selectivity ratio (SR) and discriminating variable (DIVA) test. The aim is to 
develop new quantitative tools for interpretation and variable (biomarker) 
selection in complex spectral profiles. Multivariate modelling approach based on 
PLS regression and TP is used to obtain one predictive component which in turn is 
the a starting point to variable selection and  detection of biomarker signatures. 
Methods are validated using spiked CSF samples. (Papers II and III) 
3. Application to mass spectral profiles of CSF from patients with MS. The 
developed methodology (DIVA test and SR plot) is applied for the first time to 
real proteomics data. The aim is to reveal the features distinguishing patients with 
MS from control groups OND and NHC. The detected biomarker signature can 
then be used for disease classification. (Paper IV)  
1.2 Scope and outline of the thesis 
The thesis covers some basic theory of clinical proteomics, biomarker detection, 
biological mass spectrometry, and multivariate analysis. The analytical chain starts 
from the selection of study population, and proceeds via sampling, sample 
preparation, instrumental analysis, data acquisition, and data analysis to the final 
results. This thesis has the main emphasis on the data analysis step, even though the 
other steps are also discussed to some extent. Figure 1 illustrates the proposed 
workflow starting from body fluid samples and leading to biomarker signature.  
 18 
 
Spectral data
Body fluid samples
Data pretreatment
Multivariate data analysis
Feature selection
Classification using biomarker signature  
Figure 1. Proposed workflow for pattern based biomarker detection and disease 
classification. 
 
The thesis has the following structure: Chapter 1 has given introduction to the aims 
and the scope of the thesis. Chapter 2 provides a background to “omics” sciences, 
especially clinical proteomics with emphasis on biomarker discovery. A brief 
introduction to multiple sclerosis is also given in this chapter. Proteomics techniques, 
biological mass spectrometry and MALDI-TOF instrumentation are discussed in 
Chapter 3. In Chapter 4 multivariate methods are described in detail, including SR 
plot and DIVA test, novel methods developed as part of this thesis. Chapter 5 contains 
a summary of the obtained results and general discussion. Conclusions and future 
perspectives are presented in Chapter 6. 
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2. Background 
“I could prove God statistically.  Take the human body alone – the chances that all 
the functions of an individual would just happen is a statistical monstrosity.” George 
Gallup 
Clinical laboratories are facing fundamental changes in the near future when it comes 
to methodology and instrumentation. Views of health and disease are influenced by 
the present post-genomic era, driven by huge advances in bioanalytical technologies 
and bioinformatics. The study of the human genome has been followed by the study 
of human proteome, providing us complementary information for the analysis and 
understanding of complex pathological processes. These approaches, the so-called 
“omics” sciences (Figure 2), have given a novel insight into human biology and a 
paradigm shift in healthcare is under progression. 
This chapter provides theoretical background to “omics” sciences in general, and 
especially to the field of proteomics, with the emphasis on its most important 
application and the main theme of this thesis: proteomics based biomarker discovery. 
A short introduction is also given to MS; a chronic, inflammatory disease which has 
been used as a model disease in this thesis.   
 
 
 
 
 
Figure 2. Schematic presentation of “omics” 
sciences.  
Cell
Metabolites
Proteins
mRNA
DNA
Genomics
Proteomics
Transcriptomics
Metabolomics
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2.1  “Omics” sciences 
Every living system is built from cells. All cell functions are directed by information 
provided by deoxyribonucleic acid (DNA), a molecule which in turn is made of the 
same components in all living organisms.1 DNA consists of nucleotides (containing a 
base, sugar, and phosphate) which are arranged in two long strands forming a double 
helix. Alternating phosphate and sugar (2-deoxyribose) residues compose the 
backbone of each DNA strand. One of four different bases, adenine (A), cytosine (C), 
guanine (G) and thymine (T), is attached to each sugar and hydrogen bonds between 
base pairs (A and T, G and C) hold the two strands together. The bases are arranged 
in a particular order and it is the sequence of these four bases that dictates the 
instructions required to create an organism with unique features. The complete set of 
DNA molecules for an organism is its genome and genomics aims to map the entire 
DNA sequence of a certain organism.2 The DNA sequence is divided into different 
regions. A gene is a specific region of the DNA that encodes a certain protein. Genes 
have coding regions (exons) and non-coding regions (introns); the DNA molecule is 
actually mostly consisting of non-coding regions. The protein encoding process 
consists of transcription of coding regions of DNA into messenger ribonucleic acid 
(mRNA) and translation of mRNA template into a protein sequence (Figure 3). RNA 
is a single-stranded molecule containing ribose instead of deoxyribose and the same 
bases as DNA, except for thymine (T) which in RNA is substituted with uracil (U). 
Transcriptomics is a study of all mRNA molecules reflecting the active genes.3  
Translation is based on the genetic code (Figure 4) where a triplet of nucleotides (a 
codon) in mRNA represents a single amino acid, a building block of proteins. In total 
there are 20 amino acids to choose from, thus the four-letter RNA code is translated to 
the twenty-letter amino acid code. Genes contain the recipe for the heredity by 
passing the traits from one generation to the other. International Human Genome 
Sequencing Consortium has given a recent estimate that the total number of protein-
coding genes in the human body is in the range 20 000–25 000.4 This is much less 
than originally expected and a surprisingly low number for our species. On the other 
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hand, these genes may be encoding as many as one million protein forms, that is, 
enzymes, antibodies, hormones, structural elements and electron carriers, which are 
responsible for all our vital functions. 5-7  
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Figure 3. Information flow in biological systems from nucleic acid into protein, the 
so-called central dogma of molecular biology.8  
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Figure 4. The genetic code and the 20 amino acids with their abbreviations. 
22
Proteins are large biological macromolecules made up of chains of amino acids.9
Short chains of amino acids are called peptides and proteins are therefore 
polypeptides. The primary structure of a protein is its amino acid sequence. Chemical 
properties of the amino acids cause the protein chain to fold up into a three-
dimensional structure. The overall shape of the protein (tertiary structure) is 
consisting of secondary structure elements (most commonly beta strands/sheets and 
alpha helices) connected by intermediate amino acid turns. An example of this is 
shown in Figure 5, which illustrates a crystal structure of human cystatin C.10 Proteins 
are converted to their mature form through a complicated sequence of post-
translational modifications (PTM) that generate a large number of different forms of 
the protein, with major differences in function. Many of these PTMs are regulatory 
and reversible (e.g. protein phosphorylation) and they are responsible for protein 
folding, stability, cellular localization, recognition and immune reactions. 11, 12
Chemistry and behaviour of a protein are determined not only by the coding gene but 
also by the other proteins made in the same cell at the same time due to, for example, 
protein-protein interactions. 
Figure 5. The crystal structure of monomeric human cystatin C stabilized against 
aggregation.10 Image from the Protein Data Bank (www.pdb.org), PDB ID: 3GAX.
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The proteome is the entire collection of proteins (including the PTMs, mutations and 
degradation made to a particular set of proteins) of a cell, tissue or fluid in a living 
organism at a given point in time. While the genome is relatively stable, the proteome 
is a highly dynamic system undergoing constant changes due to a large number of 
intra and extracellular environmental variations, for example, as a result of drug 
administration.  
Proteomics is the study of proteomes.13-15 Originally proteomics referred to detection 
and identification of a complete set of expressed proteins in an organism or living 
system (e.g. the human body). This has, however, changed during the recent years and 
proteomics has become a science that covers a much wider array of protein related 
features with experimental and computational approaches handling large amount of 
protein related information.16 Large-scale analysis of complex protein expression 
patterns, protein-protein interactions and PTMs is now possible because of advanced 
proteomics technologies. The field has become very popular and despite its relatively 
young age (starting at 1995) huge amount of proteomic applications have been 
published. For instance a PubMed search with the keyword “proteomics” gave 24 344 
articles (performed on April 21st 2010). The popularity has also lead to an explosion 
in protein databases such as European Bioinformatics Institute (EBI) Databases 
(www.ebi.ac.uk/Databases), Human Protein Atlas (www.proteinatlas.org), Human 
Proteinpedia (www.humanproteinpedia.org), National Center for Biotechnology 
Information (NCBI) Databases (www.ncbi.nlm.nih.gov/protein), and Worldwide 
Protein Data Bank (wwPDB) (www.wwpdb.org). 
The last link in this chain of “omics” sciences is metabolomics.17, 18 This is a study of 
metabolites; small chemical compounds produced via metabolic mechanisms 
representing the end products of the gene expression chain in an organism. The 
challenge in systems biology is to be able to integrate the information from all the 
different levels (from DNA to metabolites) to get the overall picture of the system 
itself.19
24
2.2 Clinical proteomics 
Modern proteomic research is aiming for novel methodologies that can be applied 
directly in clinical diagnosis, monitoring and controlling of therapy and designing of 
drugs. The most important and widespread use of proteomics is the identification of 
proteins in cells, tissues or biofluids under different states (e.g. a specific disease). 
Clinical proteomics is based on the hypothesis that proteins can provide information 
having diagnostic or therapeutic value. Mischak et al defined the field of clinical 
proteomics as: “The application of proteomic analysis with the aim of solving a 
specific clinical problem within the context of a clinical study.” 20 Clinical proteomics 
studies on human body fluids were first initiated in the beginning of the 2000s. A 
controversial study of a proteomic pattern in serum as a screening tool for ovarian 
cancer created huge excitement and started a flood of similar applications 
worldwide.21
Clinical proteomics aims at bringing proteomic tools into the clinical environment: 
understanding of patho-biological mechanisms and search for new diagnostic, 
prognostic or therapeutic biomarkers. The task is not easy as there are many problems 
that still need to be resolved before widespread implementation of proteomic 
techniques in routine clinical chemistry laboratories. Mass spectrometry based 
proteomic technologies have an increasing potential but further development in 
workflows and instrumentation is needed to be able to fully compete with existing 
techniques like protein immunoassays performed on high-throughput immuno-
analyzers.22 Proteomics and disease related discussions and opinions about the 
potential success of use of proteomics in clinical chemistry and especially biomarker 
discovery have been presented in several articles.5, 20, 23-28 Many of them conclude that 
the proteomic methods are not yet ready for implementation in routine clinical 
laboratories, but that it seems to be possible to reach the goal in the near future. 
Clinical proteomics is a highly interdisciplinary field where involvement from 
specialists with clinical expertise, bioanalytical chemistry, instrumental analysis and 
data analysis is needed. As mentioned before, the proteome is far more extensive than 
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the genome and measuring and analyzing proteome present a huge challenge. New 
technological and bioinformatic solutions are therefore needed to solve the problem.  
Understanding the proteome, the structure and function of each protein and the 
complexities of protein-protein interactions will be critical for developing the most 
effective diagnostic techniques and disease treatments in the future. 
There are many important considerations related to a clinical proteomic study. 
General principles and rules of clinical trials should be followed when selecting study 
population, collecting and handling samples and analyzing them.20 For example, it 
should be kept in mind that in addition to control group with healthy individuals, a 
control group with patients resembling the studied disease should be included to the 
study population. At the onset of a clinical proteomic study, a clinical problem should 
be clearly defined. The clinical relevance of the findings must be evaluated to be able 
to judge whether a new proteomic approach will result in improvements when 
compared to current standard procedure for diagnostics and therapy. In addition, 
utilizing advanced proteomic techniques in clinical environment may not always be 
cost-effective in practice.  
Pre-analytical factors like sample collection, handling and storage may have a 
significant effect on the obtained results and should therefore be standardized.20, 29
Factors affecting the instrumental analysis itself are also important to recognize. 
Availability of patient material is often limited and sample amounts are relatively 
small. Since we do not know all proteins present in a complex sample, it is desirable 
to keep the proteins intact. The workflow for sample handling should be fast so that 
time from collecting a sample to freezing it is minimized. Good reproducibility of 
sample preparation is important since large experimental variation introduced during 
this phase increases the risk of false findings as well as missing potential biomarkers.  
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2.3 Proteomics based biomarker discovery 
Biomarkers are tests or measurements that provide information about the biological 
condition of the subject being tested.30 In addition, biomarkers have an ability to 
segregate between different biological states, for example, disease affected patients 
and healthy individuals. Advances in proteomic techniques have given us the hope of 
discovering novel protein biomarkers. Detected and identified proteins or peptides 
become biomarkers after validation, that is, they must be verified and proved as 
reliable predictors for a certain condition.  
Biomarkers can be used for monitoring disease progression, for instance by looking at 
the trend from visit to visit (i.e. biomarker velocity) within a single patient. 
Pharmaceutical industry has an interest to find biomarkers that reflect drug response 
or toxicity and can be used instead of waiting for a clinical event. Biomarkers 
predicting the response for the treatment (i.e. endpoint analysis) can be used for 
monitoring the efficacy of therapeutic intervention. In disease subtype classification, 
the aim is to find biomarkers that discriminate between known subclasses or define 
novel subclasses in a patient group previously treated as homogeneous.  
Perhaps the most wanted application of biomarkers is disease diagnosis.30 This is 
particularly the case when early intervention improves the success of treatment and 
current tests do not detect disease early enough. However, demands placed on 
biomarkers used for diagnosis are much higher than those used for monitoring disease 
in existing patients. For instance, quantitative values must be established to be able to 
set boundaries between positive and negative tests.  
Proteomics has been extensively used in biomarker discovery. Comprehensive 
proteomic analysis and identification of proteins in a single sample does not provide 
us with useful biomarkers. Comparison of samples from different populations is 
needed to be able to reach the goal. Because of the “holistic” nature of the proteomic 
response to a certain disorder it is more probable that instead of one single biomarker 
there are actually multiple potential biomarkers that together can be used to diagnose 
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the disease.20 Different diseases may also have overlapping biomarkers. This makes 
the task of finding biomarkers even more complicated. 
Instead of striving for complete identification of the proteome one may take an 
alternative approach and use proteomic pattern analysis. Looking at protein patterns 
should be an effective method for the early diagnosis of diseases. A panel of observed 
biomarkers gives a signature that can be used in diagnostics without the need for 
identification of the biomarkers itself, even though identification is of course 
preferred, if achievable. Since hundreds of clinical samples per day can be analyzed 
utilizing mass spectral profiling, this technology has the potential to be a novel, highly 
sensitive diagnostic tool for the early detection of many diseases, or as a predictor of 
prognosis and response to therapy. 
Two possible routes can be used in the proteomic analysis when comparing samples 
from disease affected patients with control groups and looking for differences in 
protein contents (Figure 6).23 
 
Samples
Fractionation
(chromatography) 
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Figure 6. Identification-based biomarker discovery versus pattern-based diagnostic 
proteomics. 
28
In identification-based biomarker discovery multidimensional fractionation of 
samples in combination with tandem mass spectrometry analysis is used. Hundreds of 
proteins that are unique or highly abundant within samples can be identified using this 
approach. The strategy is very time consuming and is hence setting the limit to 
number of samples that can be compared. Data analysis is based on peak detection 
and univariate statistics where peaks are compared using, for example, t-tests. 
Pattern-based diagnostic proteomics employs high-throughput methods based on 
technologies like surface-enhanced laser desorption/ionization (SELDI) and MALDI 
mass spectrometry. A protein profile is acquired and bioinformatic data analysis 
methods are employed to search for differences in peak intensities between the sets of 
different sample groups. The method does not rely on the identification of the proteins 
itself, only the pattern, although selected peaks can be subjected to further analysis 
and identification.   
Clinically relevant biomarkers have to undergo four phases: discovery, qualification, 
verification, and validation with assay development.31 Mass spectrometry based 
techniques are suitable for the discovery phase since they can be used to measure 
differences in profiles between clinical samples. Full instrumental profiling of 
proteins generates high-dimensional datasets where the number of variables is much 
higher than the number of samples. This can easily give rise to false biomarkers when 
using traditional statistics. Validation of the potential biomarkers is the final step in 
the process and should be done with independent samples left out in the analysis 
phase or collected later for repeated analysis. 
2.3.1 Some statistical considerations for biomarkers 
Currently the main focus in biomarker applications is on their use as clinical tests.30
Such tests can have two outcomes reflecting the true presence or absence of a certain 
clinical state, thus the result can be positive or negative, respectively. Even in cases 
where it is possible to obtain a quantifiable test result the common practice is often to 
set a threshold value which defines the borderline between negative and positive test. 
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Two types of errors can be defined if the test fails. False positives occur when 
positive test results are obtained in the absence of disease (case b, Figure 7). False 
negatives occur when negative test results are obtained in the presence of disease 
(case c, Figure 7). In both cases the consequences can be dramatic and cause 
unnecessary stress, further diagnostic procedures and treatment, or even mortality.  
Sensitivity measures the ability of the test to find the disease when it is present, that 
is, the fraction correctly classified as positive in a population having the disease 
(a/(a+c), Figure 7). Specificity measures the ability of the test to rule out the disease 
when it is absent, that is, the fraction correctly classified as negative in a disease-free 
population (d/(b+d), Figure 7). 
Disease
Test Present Absent 
Positive a b 
Negative c d 
 Figure 7. Possible outcomes of a clinical test.  
In reality many diseases do not comply with this kind of binary black and white 
thinking, thus giving a grey zone in between. Let us consider the case of two 
populations, disease affected and healthy individuals, and calculate the mean value 
for the biomarker variable for each of the populations. If we then compare these 
means using statistical tests like t-test, there is a risk that the variation around the 
mean is so broad that the populations actually overlap to such a degree that it is 
impossible to define a clear cut-off value that can be used to separate the populations 
(Figure 8). But even if no clear separation can be provided using an individual 
biomarker it may be possible to achieve this goal using several biomarkers jointly, as 
illustrated in Figure 9 for two correlated variables. Multivariate methods take into 
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account correlation patterns between variables and thus enable the discrimination 
between samples in this type of situations as well. 
 
DiseaseNormal
Biomarker value
Grey zone
xnormal¯ x¯disease  
Figure 8. Distribution around mean value for a biomarker variable when comparing 
two different populations. Populations are overlapping each other and there is a grey 
zone in between the populations.  
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x 2
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Figure 9. A case with two groups and two correlated variables. No discrimination 
can be observed if the variables are considered separately.  
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2.3.2 Proteomic analysis of body fluids 
An adult human body consists approximately 60% of fluids.32 Human body fluids, 
such as blood, saliva, CSF and urine, are believed to reflect the tissues present within 
a patient. Characterization of the proteomes from various body fluids has recently 
been under extensive interest.23, 26, 33 Proteomics techniques, such as mass 
spectrometry, can be used to screen and identify hundreds of proteins in complex 
body fluids (see Chapter 3). The analytical tools have become more sophisticated, but 
discovery of biomarkers in biological fluids is still an enormous challenge because of 
the huge amount of proteins present in these fluids.  
A ‘proximal’ fluid is defined as a body fluid having a direct contact with the disease 
affected organ.31 Proteins or peptides secreted from diseased tissue can therefore be 
detected directly from proximal fluids, a property that makes them an attractive source 
for biomarker discovery. Proximal fluids include for instance urine (biomarkers for 
bladder and kidney diseases) and CSF. CSF surrounds and protects the central 
nervous system (CNS) from trauma. It is a clear liquid that is produced in the 
ventricles of the brain, which in turn are continuous with the central canal of the 
spinal cord. CSF is the only clinical material obtained from a living person that has a 
direct contact with the extracellular surface of the brain. Therefore CSF is a natural 
body fluid of choice for analysis of biochemical changes in the CNS and searching 
biomarkers for neurological diseases. A limiting factor for collecting CSF samples 
may be the invasive procedure of lumbar puncture, since usually a blood sample or 
even non-invasively collected samples are preferred.  
CSF proteome resembles plasma proteome since around 80% of the proteins found in 
CSF are derived from blood.34 The remaining 20% of the proteins originate from 
brain and many of these proteins are among the most abundant ones in the CSF (Table 
1). The total protein concentration in CSF is approximately 350 mg/L, that is, about 
200 times lower than in plasma. But like in plasma samples, depletion of high-
abundant proteins like albumin, that mask more interesting low-abundant proteins, is 
required prior to proteomic profiling. Characterization of the CSF proteome from 
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neurologically normal individuals as well as patients with a certain neurological 
disease has been in focus in recent years. Several studies show that alterations in 
protein profiles of CSF may reflect abnormalities associated with a diverse array of 
neurological diseases, for example, traumatic brain injury, neurodegenerative 
disorders, MS, and hydrocephalus.35-42 Even though many proteins have been 
identified it has not always been determined whether these proteins are causally 
related to the disease or not. 
It is clear that a large diversity of neurological diseases could benefit from profiling of 
CSF proteome and subsequent identification of protein biomarkers. These markers 
can then be associated with onset and progression of a disease as well as predicting 
response to therapy. 
Table 1. The most abundant proteins and their concentrations in the cerebrospinal 
fluid (CSF) and plasma.34 Brain derived CSF proteins are marked with an asterisk.  
CSF proteins Conc. (mg/L) Plasma proteins Conc. (mg/L) 
Albumin 200 Albumin 45 000 
Prostaglandin D-synthase* 26 IgG 9 900 
IgG 22 -lipoprotein 3 000 
Transthyretin* 17 Fibrinogen 3 000 
Transferrin 14 Transferrin 2 300 
1-antitrypsin 8 -lipoprotein 2 000 
Apo-lipoprotein A 6 2-macroglobulin 2 000 
Cystatin C* 6 1-antitrypsin 1 400 
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2.4 Multiple sclerosis (MS) 
MS is a chronic, immune-mediated disease of the central nervous system (CNS). A 
triggered immune system is causing an inflammatory demyelination (loss of myelin, 
the protective sheath surrounding nerve fibres of CNS), axonal damage (destruction 
of nerve fibres) and often followed by irreversible neurological disability. MS has an 
unpredictable clinical course and shows usually a gradual accumulation of disability 
(both physical and cognitive), with major impact on normal family life and social 
roles. However, the outcome of the disease is heterogeneous and therefore at present 
impossible to predict for an individual patient.43, 44 The cause of the disease is 
unknown, but it is believed that MS is a result of interplay between genetic and 
environmental factors. No curative treatment exists, but several disease modifying 
preparations are available.44  
2.4.1 Epidemiology 
MS is estimated to affect about 2.5 million individuals worldwide, and it is the most 
common, non-traumatic cause of disability in young adults.43 Epidemiological studies 
have shown that there is a large variation in the geographical distribution of MS. The 
prevalence varies with latitude being higher the farther from the Equator one lives. 
Northern and central Europe, USA, Canada, Australia and New Zealand are 
considered as high-risk areas.45 The prevalence of the disease ranges between 2 and 
150 per 100 000 inhabitants, depending on the country or specific population. The 
prevalence rate in Norway is probably above 150 per 100 000,46 but being lower in 
the northern parts of the country.47 This difference in distribution may imply 
differences in both genetic and environmental risk factors. 
The disease appears most often between 20-40 years of age, but it can also appear in 
children, and females are more affected than males.46, 48 A ratio of 2:1 is typically 
reported, and recent studies suggest an increasing incidence for women, indicating 
gender specific changes in environmental risk factors.49-51  
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The cause of MS is unknown. Many putative environmental risk factors have been 
suggested but only a few have been confirmed to an increased risk of developing the 
disease.52 These include sunlight exposure and vitamin D, infection with Epstein-Barr 
virus, and smoking.53 About 20% of patients with MS have at least one affected 
relative, indicating genetic risk factors. Association to human leukocyte antigen 
(HLA) genes have been known for many years.54 But recently, several other immune 
related genes have been identified, amongst them IL2RA and IL7RA, and the number 
is increasing. 55, 56
2.4.2 Symptoms and clinical subtypes 
The symptoms of MS are caused by lesions in the CNS and reflect the part of CNS 
which is involved. Typical clinical symptoms at the onset are numbness or 
paresthesia, weakness in upper or lower extremities, optic neuritis, double vision and 
dizziness, and coordination difficulty.44  
The disease may be divided into relapsing remitting MS (RRMS), or primary 
progressive MS (PPMS) according to the initial disease course (Figure 10). RRMS 
account for 80-85% of the patients and is characterized by a series of unpredictable 
relapses with full or partial recovery in between. A relapse is defined as significant 
worsening of pre-existing symptoms or appearance of new neurological symptoms 
characteristic for MS which are developing over days or weeks, lasting at least 24 
hours, and are not associated with fever or intercurrent illness.57, 58 Approximately 
50% of the patients with RRMS experience a gradual decline and convert to 
secondary progressive MS (SPMS) within 10-15 years of disease onset.59 In PPMS 
the disease gradually progresses with steady increase in disability without any periods 
of relapses or recovery. In addition to these three subtypes, clinically isolated 
syndrome (CIS) is often referred to as a first indication of the disease.  
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Figure 10. Clinical subtypes of MS. The figures illustrate the two main initial (onset) 
courses of MS, relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), 
and the subgroup of secondary progressive MS (SPMS). 
2.4.3 Diagnosis and treatment 
Diagnosing MS may be challenging. There is no single test to make a definitive 
diagnosis and signs and symptoms of MS may be similar to other neurological 
problems. Therefore, diagnostic criteria have been created to ease and standardize the 
diagnostic process for physicians. Currently, the McDonald57 and the revised 
McDonald criteria58 focus on a demonstration of the dissemination of MS lesions in 
time and space (Table 2). The diagnosis is based on disease history and clinical 
examination combined with visualization of lesions with magnetic resonance imaging 
(MRI) (Figure 11) and detection of oligoclonal bands of IgG and barrier index in the 
CSF. In general, to make a diagnosis of MS, an individual must have 2 episodes of 
neurological symptoms referable to the CNS that are separated in space and time and 
that are not attributable to any other cause. Repeated MRI examinations can, however, 
substitute one of the clinical episodes. It may be time-consuming to establish a correct 
diagnosis and thus valuable time can be wasted in the first stages of the disease. In 
addition, subclinical disease activity with irreversible damage may occur even before 
the first clinical symptoms are detected. Early therapy usually slows down disease 
activity,60 and might be important for the long time prognosis of the disease.44 Thus, 
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there is a definitive need for sensitive and specific tests like disease biomarkers to 
enable an early diagnosis. No cure is available, but corticosteroids can be used to 
shorten relapses, various symptomatic treatments exist, and several long-term, disease 
modifying therapies are available.59
Figure 11. T2-weighted magnetic resonance 
image (MRI) showing typical periventricular 
hyperintensive multiple sclerosis lesions. 
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Table 2.  Revised McDonald diagnostic criteria for multiple sclerosis (MS).58
Clinical presentation
Attacks Lesions Additional data needed for diagnosis
2 2 
None. But MRI and CSF analysis should be done to 
exclude other diagnoses. If these tests are negative,
extreme caution needs to be taken before making a 
diagnosis of MS. 
2 1 
Dissemination in space, demonstrated by:   
o MRI or two or more MRI-detected lesions 
consistent with MS plus positive CSF  
or  
o Await a further clinical attack implicating a 
different site 
1 2 
Dissemination in time, demonstrated by:   
o MRI  
or  
o A second clinical attack 
1 1 
Monosymptomatic presentation; 
clinically isolated syndrome (CIS) 
Dissemination in space, demonstrated by:   
o MRI or two or more MRI-detected lesions 
consistent with MS plus positive CSF 
and 
Dissemination in time, demonstrated by:  
o MRI  
or  
o A second clinical attack 
Insidious nervous system 
progression suggesting primary 
progressive multiple sclerosis 
(PPMS) 
One year of disease progression (retrospectively or 
prospectively determined) and two of the following: 
o Positive brain MRI (nine T2 lesions or four or 
more T2 lesions with positive VER) 
o Positive spinal cord MRI (two focal T2 lesions) 
o Positive CSF 
MRI, magnetic resonance imaging; CSF, cerebrospinal fluid; VER, visual-evoked response 
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3. Instrumentation 
“Technology is dominated by two types of people: those who understand what they do 
not manage, and those who manage what they do not understand.” Putt's Law 
Proteomics is built on technologies that enable the analysis of a large number of 
proteins in a single experiment. However, there is no single technique capable of 
detecting all proteins in complex biological samples like body fluids or cell and tissue 
extracts. 
This chapter provides a brief introduction to proteomics techniques used in the 
analysis of body fluids, and instrumentation in general. The main focus is on the use 
of biological mass spectrometry, and a detailed description of MALDI-TOF, the 
technique used in this thesis, is given. 
3.1 Proteomics techniques 
The overall proteomics strategy can be divided into four subsequent steps, that is, 
sample preparation, protein separation, identification and characterization (Figure 
12).32 Each step in this pipeline is equally important for the overall success and 
involves techniques with technical challenges. 
Sample
preparation
 Sampling
 Storage
 Pretreatment
Protein 
separation
 Chromatography
 Electrophoresis
 Affinity approaches
Protein 
identification
 N-terminal sequencing
 Mass spectrometry
Characterization
 PTMs
 Cellular localization
 Conformation
 etc.
 
Figure 12. Pipeline of proteomics techniques. 
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Sample preparation, including preanalytical procedures like sample collection, 
storage, and pretreatment, may have a significant role in the overall analytical result. 
Preanalytical effects may alter the proteome and thus give rise to false biomarkers. 
Each body fluid requires an adapted sample preparation protocol tailored to the 
specific needs of the analytes in question.61 Development of such a protocol is beyond 
the scope of this thesis. In an earlier published work, however, we have reported the 
preanalytical influence on the low molecular weight (MW) proteome of CSF.29 Issues 
like blood contamination, different sample storage conditions, and different types of 
MW cut-off filters are included in this prestudy. The recommended protocol is 
applied to the proteomic study of CSF samples in this thesis (described in detail in 
Section 5.1). 
When analyzing human body fluids, one challenge is how to handle the extreme 
complexity of the samples; for example, blood plasma may contain more than one 
million protein forms.32 Another challenge is the large dynamic range of protein 
concentrations present in the samples.62 For instance, in plasma proteome two 
clinically useful proteins, serum albumin (at the high abundance end) and interleukin 
6 (at the low abundance end), differ by 10 orders of magnitude.63 Proteins with high 
abundances can dominate in such a high degree that the instruments are not sensitive 
enough to measure the proteins with low abundances. Good separation techniques are 
therefore needed to make the protein mixtures less complex and thus enable mass 
spectral analysis and subsequent identification. The target proteins can be enriched 
using prefractionation methods with which the most abundant proteins masking the 
low abundance proteins are removed. In the actual fractionation procedure, the 
maximal separation between the different proteins is desired. An overview of the 
approaches used in proteomic analysis of body fluids is presented in Figure 13.61  
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Figure 13. Overview of different approaches in body fluid proteomics. 
 
The body fluid proteome can be divided into high and low MW fractions (also 
referred to as the peptidome) to detect small proteins and peptides with low 
abundances. One way to achieve this is to utilize MW cut-off filters.64, 65 Only 
proteins below a chosen threshold can pass through the filter, thus giving a good 
enrichment of the smaller proteins and peptides.  
The most widely used separation technique has traditionally been two-dimensional gel 
electrophoresis (2DE).66-68 The method is a combination of two separation techniques, 
isoelectric focusing and sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), and it separates complex mixtures into single protein spots based on 
their isoelectric point (pI) in the first dimension and size (Mr) in the second 
dimension. After separation the protein spots are stained (e.g. silver or coomassie 
staining) to enable visual inspection. The spots can be removed from the gel by 
cutting and then subjected to tryptic digestion and identification by mass spectrometry 
(usually MALDI-TOF). Even more than 5000 proteins can be simultaneously resolved 
in one gel.69 However, the loading capacity of 2DE gels is limited making the 
detection of low-abundance proteins very difficult without proper prefractionation. 
Other problems associated with 2DE are, for example, poor reproducibility and 
41
laborious analytical work-up, which make it unsuitable for the analysis of large series 
of clinical samples. 
In chromatographic separation methods the proteins in the sample distribute between 
the stationary and mobile phases. Chromatography can be used as a prefractionation 
tool or it can be coupled directly to mass spectrometry (so-called hyphenated 
techniques).70-72 Affinity chromatography is the most commonly used prefractionation 
method when analyzing body fluids. In affinity chromatography the proteins are 
separated based on their binding to other molecules such as antibodies. The method is 
mainly used for removal of the most abundant proteins, for example, albumin and 
immunoglobulin G (IgG). Also ion-exchange chromatography and reverse phase 
high-performance liquid chromatography (RP-HPLC) can be utilized in 
prefractionation. Chromatographic separation can also be combined with 2DE giving 
a third orthogonal dimension for protein separation. In the so-called shotgun 
proteomics the entire proteome is first digested into peptides, followed by one- or 
multidimensional chromatographic separation prior to analysis with mass 
spectrometry.73
Several techniques are developed and can be used to detect, identify and measure 
hundreds or even thousands of proteins. SELDI, MALDI, capillary electrophoresis 
(CE) and multiple reaction monitoring (MRM, also known as selected reaction 
monitoring, SRM) are all mass spectrometry based methods having a potential to be 
applied in clinical chemistry laboratories.22 SELDI, MALDI and CE are profiling 
methods providing proteomic fingerprinting of samples while SRM appears as a 
potential alternative to classical immunoassays by combining analytical specificity 
and reliable quantification. 
SELDI utilizes different adsorptive surfaces to bind a certain subgroup of proteins. 
The bound proteins or peptides are then analyzed using the same principle as in 
MALDI mass spectrometry. The technique has been commercialized under the name 
ProteinChip®.74 Samples are loaded onto the ProteinChip array coated with a 
chemically treated surface (e.g. hydrophobic or hydrophilic). The unbound proteins 
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are washed away, and the bound proteins are mixed with an energy-absorbing matrix 
and subjected to mass spectral analysis. In MALDI a sample is mixed with a matrix, 
deposited directly on a MALDI plate and targeted with the laser beam. MALDI 
method is described in detail in Section 3.3.  
In CE mass spectrometry, fractionation using CE is combined with mass spectrometry 
detection.75 In CE, high-efficiency separation is achieved by applying high voltages to 
generate electro-osmotic or electrophoretic flow of buffer solutions and ionic species 
within narrow-bore capillaries. MRM has recently become available also for 
proteomic analysis due to technical development of mass spectrometers (i.e. triple 
quadrupoles). In the first quadrupole mass of the parent ion is selected. In the second 
quadrupole the parent ion is fragmented by collision. Finally, in the third quadrupole, 
a specific fragment of the parent ion is selected. 
3.2 Biological mass spectrometry 
Mass spectrometry is one of the most powerful instrumental techniques in analytical 
chemistry. It can measure a panel of analytes in a single assay thus allowing, for 
example, full profiling of the body fluid samples. Advances in mass spectrometry 
technology have made today’s proteomics research possible.  
In mass spectrometry the measurements are carried out in a gas phase. Therefore the 
sample has to be first volatized and ionized using an ion source. The generated ions 
are guided to a mass analyzer where they are separated based on their mass-to-charge 
ratio (m/z). A detector then registers the number of ions at each m/z value. The output 
signal is acquired and presented as a spectrum of measured m/z values for each 
analyzed sample. A schematic presentation of a mass spectrometer is shown in Figure 
14. 
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Figure 14. A mass spectrometer consists of three parts: ion source, mass analyzer 
and detector. Mass spectrum is generated from the detector signal using computer. 
 
For the analysis of large polar biomolecules like proteins, soft ionization techniques 
are employed. Using electrospray ionization (ESI) and MALDI the molecules remain 
relatively intact. ESI ionizes proteins or peptides out of a solution and it can be 
coupled directly to separation techniques like liquid chromatography (LC).76 The 
sample solution is supplied as a continuous flow through a needle creating an aerosol. 
The solvent evaporates and positively charged molecular ions are formed. MALDI 
sublimates and ionizes proteins or peptides out of a dry matrix using laser pulses. 
These ionization sources can be interfaced to different mass analyzers. In proteomics 
research the most commonly used mass analyzers are time-of-flight (TOF), 
quadrupole, ion trap, and Fourier transform ion cyclotron resonance (FT-ICR) 
analyzers. The operation of quadrupole and ion trap mass analyzers is based on ion 
motion in radio frequency electric fields.77 The resolution and accuracy of these 
instruments is not very high. FT-ICR instruments, on the other hand, have extremely 
high performance, and separate the ions based on their cyclotron frequency in a fixed 
magnetic field.78 TOF mass analyzer is described in detail in the next section. 
3.3 MALDI-TOF mass spectrometry  
MALDI source coupled to TOF mass analyzer is one of the most common interfaces. 
MALDI-TOF offers a rapid approach to the analysis of intact proteins in body fluid 
samples. It is a relatively simple method with excellent mass accuracy, high resolution 
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and sensitivity all of which makes it ideal for high-throughput profiling of proteomic 
samples.11 In addition, MALDI-TOF is cost-effective and the instruments are easy to 
operate demanding relatively simple analytical work-up. Working mass range of TOF 
analyzers is large (approx. 100 Da to 250 000 Da) and only singly charged molecular 
ions are observed in MALDI ionization.77  
In MALDI the biomolecules are caught within a crystalline structure, referred to as a 
spot, and bombarded with laser pulses. This bombardment is usually repeated several 
times at different positions in a spot, thus generating an average spectrum. Intensity 
variations, which can be observed even between the spots originating from the same 
sample, can be reduced in this way. Sample preparation is crucial in MALDI since the 
type of matrix and presence of possible impurities affect the generated ions. Features 
like chemical properties of the matrix, its proportion to the analyte and the way it co-
crystallizes with the sample all affect the spectra and their reproducibility.26, 79, 80
MALDI-TOF is not regarded as a quantitative technique, but studies have shown that 
optimization makes it possible to reduce analytical variance substantially making the 
MALDI-TOF and similar mass spectrometry approaches produce more quantitative 
results. 81, 82 It should be noted that protein identification is not possible using 
standard MALDI-TOF since proteins cannot be identified based on their molecular 
weight only.  
3.3.1 MALDI ionization 
MALDI ionization was introduced for the first time in the late 1980s by Koichi 
Tanaka and Franz Hillenkamp, following application of use of lasers for the 
ionization and analysis of biomolecules.83, 84 The decisive factor was the use of 
matrix, which makes it possible to perform the ionization without destroying large 
organic molecules. 
The principle of MALDI ionization is illustrated in Figure 15. Non-volatile samples 
are mixed with an excess of light-absorbing matrix in an aqueous or organic solvent. 
 45 
Matrices are usually small organic acids having conjugated aromatic ring structure, 
e.g. -cyano-4-hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB). 
A small amount of this mixture is then introduced onto a MALDI sample plate. The 
solvent is evaporated and a layer of co-crystallized mixture of sample and matrix is 
obtained.85, 86  
The sample plate is placed in the mass spectrometer under high vacuum and is 
irradiated with a pulsed laser beam (e.g. nitrogen laser at 337 nm).11, 77, 87 With laser it 
is possible to deliver coherent and high density energy to a small space. The matrix 
absorbs energy at the wavelength of the laser while the sample itself remains intact. 
The matrix is sublimated and the mixture of sample and matrix is rapidly expanded 
into the gas phase. In the formed dense cloud, the energy is transferred from matrix to 
sample and desorption occurs by proton transfer. Singly charged molecular ions are 
produced since analytes in the sample usually accept a proton. Desorption process is 
followed by desolvation and subsequent introduction into mass analyzer. A packet of 
ions with different m/z values is generated.  
 
MALDI sample plate
Pulsed
laser
Mass
analyzer
Ions
 
Figure 15. Principle of matrix assisted laser desorption/ionization (MALDI). The 
sample and an excess amount of matrix are mixed and exposed to laser irradiation. 
Both neutral molecules and ions are desorbed. The gaseous ions are guided further to 
mass analyzer and detector.  
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3.3.2 TOF mass analyzer 
TOF mass analyzer measures the mass of an ion by determination of mass-to-charge 
ratio (m/z) from its flight time.77, 85 TOF analyzer has a large mass working range, a 
feature that makes it ideal for analyzing e.g. intact proteins.  
Gaseous ions produced by MALDI are guided to TOF analyzer where they are 
accelerated using fixed potential difference (e.g. 20-30 kV) into a field-free flying 
tube. Since all the ions are exposed to the same potential, all similarly charged ions 
will have same kinetic energies. When ions pass through the field-free region they are 
separated according to their velocities; ions with larger mass have lower velocities 
than ions with smaller mass. The ions hit the detector at the end of the flying tube and 
a signal is produced. TOF mass spectrum is the detector signal as a function of time. 
The flight time (i.e. all ions have the same start time, and the arrival time is recorded 
at the detector) for each individual ion is proportional to the square root of the m/z of 
a particular ion. Axis of the spectrum can be converted into an m/z ratio axis thus 
producing the conventional mass spectrum.  
TOF can be used in either linear or reflector mode.77 In linear mode the ions fly 
through a linear flying tube and their m/z is determined by the time required for the 
ions to reach the detector. In reflector mode, a reflecting field at the end of the flying 
tube is used. The ions turn around in the reflector and then hit the detector that 
amplifies and counts the ions. Use of reflector compensates for slight differences in 
kinetic energies which may occur even though the mass is the same. The result is 
sharper peaks in the spectrum.  
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4. Multivariate data analysis 
“Then there is the man who drowned crossing a stream with an average depth of six 
inches.” W.I.E. Gates 
It should be kept in mind that measured data is not the same as information. Therefore 
an important issue in all empirical sciences, including proteomics, is how to reveal the 
relevant information in the data. For example, Spiegelman et al. 88 argue that 
“Rigorous application of sound statistical and chemometric principles will benefit the 
overall scientific community by improving protein biomarker discovery and 
validation.”  
Chemometrics can be defined as “information aspects of chemistry” 89 where 
statistical and mathematical methods are used i) to produce “good data” and ii) to 
extract relevant information out of measured data. The first aim can be achieved by 
using design of experiments (DoE) to provide a minimum number of information-rich 
experiments. Multivariate data analysis can be employed for the second purpose. In 
addition visualization of the data is an important issue and can be seen as part of 
chemometrics. The methods used in chemometrics are fully applicable in biosciences 
as well as other empirical sciences. In proteomics multivariate projection methods 
developed in chemometrics can be used to simplify complex proteomic data and make 
the visualization of spectral fingerprints easier. Furthermore, they make classification 
of samples and detection of biomarker signatures possible. 
This chapter describes chemometric methods used in this thesis. Data pretreatment 
methods are presented in the first section. DoE and empirical modelling including 
multiple linear regression (MLR) are discussed in the second section. The third 
section describes latent variable methods including classification. Variable selection 
methods are discussed in the last section. The emphasis is placed on the two new 
methods developed as part of this thesis, selectivity ratio (SR) and discriminating 
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variable (DIVA) test. More philosophical articles about chemometrics can be found 
elsewhere in the literature.89-93   
4.1 Data pretreatment 
The acquired spectral profiles are arranged in a way that each row in a table 
represents one sample and each column one measured m/z number (Figure 16). There 
are many experimental and instrumental effects that are not related to compositional 
differences between samples and thus make comparison of mass spectral profiles 
from different sample groups difficult. Examples of sources of variation are, for 
example, sample collection and storage, sample preparation and instrumental 
artefacts. In order to remove these disturbing factors and ensure that all the collected 
spectra can be analyzed jointly, proper data pretreatment is necessary prior to data 
analysis. Pretreatment has a significant effect for the final results and should therefore 
be considered carefully. Crucial factors affecting the data analysis are baseline 
effects, shifts in m/z values (alignment problem), structured noise (heteroscedasticity), 
and differences in signal intensities caused by analytical workup and the instrumental 
technique (normalization problem). Other pretreatment steps to be considered are 
smoothing and data reduction. 
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Figure 16. A spectrum is acquired for each sample and the data (intensities) are 
compiled in a table (matrix X, M×N) where each row represents one sample and each 
column one m/z number.  
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4.1.1 Baseline correction 
All mass spectra have a varying baseline. The baseline is an m/z dependent offset 
which needs to be subtracted without simultaneously removing compositional 
information in the spectrum. Baseline effects differ a lot between different mass 
spectrometric techniques, and several approaches have been proposed for baseline 
correction.94-96 Most instrument vendors have implemented their own algorithm for 
baseline correction. However, the results are not perfect and some algorithms yield 
negative intensities in the spectral profiles. In this thesis the problem of negative 
intensities has been corrected using two methods: negative spectral intensities can 
simply all be substituted with zero (Paper IV) or they can be corrected by assigning 
zero intensity to the lowest signal in each spectrum (Papers I-III). In the latter 
approach the whole spectrum is lifted by adding the absolute value of the largest 
negative intensity to the intensities at each m/z number throughout the entire profile 
and independently for each of them. 
4.1.2 Smoothing 
Noise in mass spectra may lead to problems when cross-correlation algorithms are 
used for alignment of the spectra. This problem may be reduced by smoothing the 
data. Smoothing acts like a filter where the aim is to increase the signal-to-noise ratio 
without distorting the signal. Moving average and Savitzky-Golay are the most 
common methods used for smoothing. Moving average creates a series of averages 
for subsequent subsets (with fixed window size) over the entire data set. The 
Savitzky–Golay method is based on local polynomial regression on a series of values 
to determine the smoothed value for each point.97 In this thesis, moving average 
method with a window size of 10 is used.  
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4.1.3 Alignment 
In all multivariate analysis an underlying assumption is that each column of the data 
matrix represents the same variable in all samples. Otherwise we cannot expect to be 
able to extract correct information from the data, for example, when comparing 
spectral profiles. Even small shifts in a series of spectral profiles, may cause large 
inconsistencies and serious reduction of the cross-correlation between chemically 
similar profiles. The problem of m/z shift between corresponding molecules in 
different spectral profiles is called the alignment or synchronization problem, and it 
represents an obstacle to the comparison of full spectral profiles.  
One very common solution to avoid the alignment problem is to reduce spectral 
profiles to peaks. Unfortunately this peak picking approach leads to loss of 
information in complicated spectra due to overlapping peaks. A better approach is to 
use techniques that maximize cross-correlation between a set of spectral profiles. 
Andersson and Hämäläinen developed a method where cross-correlation between 
selected target peaks present in all profiles was maximized using Simplex 
optimization.98 Entire instrumental profiles were shifted piecewise and independently 
according to the optimal fit with the target peaks. In correlation optimized warping 
(COW) linear stretching and compression is used to cross-correlate piecewise the 
profiles to a target profile.99 Both these methods were originally developed for 
chromatographic profiles. According to our experience, the COW method is time-
consuming when working with complex spectral profiles. Wong et al. developed 
cross-correlation methods based on fast Fourier transform.100, 101 In this thesis all 
spectra are aligned to an average spectrum using recursive alignment by fast Fourier 
transform (RAFFT) cross-correlation function with window size 20. Similarly to 
COW, this method aligns the profiles piecewise and optimizes cross-correlation 
between reference spectrum and profiles to be aligned for each segment.  
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4.1.4 Data reduction 
Full spectral profiles are truly multivariate. Each profile is described by tens of 
thousands of variables and huge data sets are thus provided for a set of samples. This 
may in turn give rise to data processing problems. Peak picking is one way to avoid 
this problem, but as mentioned earlier, reduction of profiles to peaks leads to loss of 
information. Other methods used for data reduction are maximum-entropy reduction 
and binning. Maximum-entropy method assumes that the information content is 
higher in regions with high intensity.102 In proteomics data, however, the low intensity 
regions may in fact contain more information than the high intensity regions. 
Therefore the low intensity regions should not be reduced more than the high intensity 
regions.  
In this thesis data reduction is achieved using binning. Binning is performed by 
adding adjacent m/z numbers throughout the spectrum using a fixed window size. A 
“good” description of the features in the profiles should be retained and the window 
size should be chosen according to the number of points needed to describe a typical 
peak in the profile. For instance, if a peak is originally described by 100 m/z numbers, 
a window size of 10 would usually be appropriate to balance between the time needed 
for data processing and still retaining the spectral features.  
Both binning and maximum-entropy has an additional effect of smoothing the spectra. 
Therefore smoothing is not used if binning is performed.  
4.1.5 Structured noise and heteroscedasticity 
Structured noise represents a major problem when comparing mass spectral profiles.  
Increasing noise with increasing signal size is called heteroscedasticity. This type of 
noise influences normalization and gives false negative correlations between major 
peaks.103, 104 It also impacts the minor peaks by giving false positive correlations 
between them. Therefore heteroscedastic noise should be transformed to 
homoscedastic noise prior to data analysis. 
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Logarithmic or nth-root transformations have been used to provide a homoscedastic 
noise pattern.103 Figure 17 visualizes the phenomenon and shows the effect of 
different mathematical transformations on heteroscedasticity. The logarithmic 
transformation destroys linear correlations in the profiles. This is a problem in 
spectral profiles where one component is described by many linearly correlated m/z
numbers. The nth-root transformation preserves perfect linear correlation, but reduces 
correlations in regions with only partial correlation. Furthermore, the nth-root 
transformation reduces the intensity of major peaks compared to minor peaks. This 
feature may in fact turn out to be an advantage since the information content in minor 
peaks may in many cases be higher than in major peaks. In this thesis, the nth-root 
transformation is used to correct for heteroscedasticity. 
A B C
Figure 17. Example of heteroscedastic noise and the effect of different 
transformations. Standard deviation versus mean intensities for baseline corrected 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry data. A) No transformation B) Square root transformation C) Log 
transformation. 
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4.1.6 Normalization 
Signal intensities between spectra derived from a certain molecule having the same 
concentration in different samples can vary a lot. This is due to factors like sample 
handling, compositional differences in the samples, distribution in the matrix and 
multiplicative effects. This means that the acquired profiles are not directly 
comparable with each other. Without internal standards, mass spectral data are usually 
normalized to create profiles with relative intensities. The most common methods 
used are normalization to constant sum or constant length.  
Normalization to constant sum: 

=
=
N
j
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1
TT xxz   i = 1,2,…M  (1) 
In Eq. 3, xi and zi represent the profile for sample i before and after normalization, 
respectively. N is the number of points describing the profile and M is the number of 
instrumental profiles acquired. The transpose is indicated by a superscript T. Vectors 
are by default column vectors and transpose transforms them into row vectors. It 
should be noted that the so-called TIC normalization, as implemented by Conrad et 
al.,105 differs from normalization to constant sum only by a scalar. 
Normalization to unit length (the norm): 
iii xxz
TT
=    i = 1,2,…M  (2) 
Spectral regions with higher intensities get larger weight when the normalization to 
unit length is used. This means that the method is more sensitive to heteroscedastic 
noise compared with normalization to constant sum. To avoid this problem the 
profiles should be properly corrected for heteroscedasticity prior to normalization. In 
this thesis normalization to unit lenght is used, but calculations confirm that there are 
no real differences between the two procedures when heteroscedasticity is first taken 
care of.  
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4.2 Design of experiments (DoE) and empirical modeling 
The purpose of an experiment is to obtain new information. To understand why 
certain experimental conditions give good results it is essential to realize why other 
conditions do not. This means that we have to introduce variation to the variables and 
thus perform experiments with both desired and undesired outcome. An empirical 
model based on the experimental data can then be estimated and used for 
interpretation and prediction. The quality of obtained information is dependent on the 
set of all experimental runs, that is, the experimental design.106  
Models can be seen as tools to estimate reality. All models are more or less erroneous, 
since there is always noise in the data. Experimental error is a variation produced by 
both known and unknown disturbing factors that may disguise important effects 
wholly or partially. These confusing effects can be reduced by using experimental 
design and statistical analysis yielding measures of statistical qualities for estimated 
variables. 
Confusion of correlation with causality is a common problem in all empirical 
research. Correlation between two variables often occurs because they are both 
associated with a third factor meaning that correlation does not automatically imply 
that the two variables have causal relationship. When data are generated using 
experimental design we can calculate the real effects and reveal the causality behind 
the studied phenomena. In addition not only linear and additive effects but also effects 
of the interactive and non-additive kind may be estimated by using experimental 
design. 
The measurable result of an experiment depends on the experimental conditions, that 
is, variables that can be controlled by the experimenter. 
 Result = f(experimental conditions)  (3) 
In empirical modelling the objective is to investigate how these controlled variables 
influence the result. In addition it is possible to optimize the system, that is, to find the 
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optimal variable settings to obtain the best result. These objectives can be achieved by 
means of a model, where the observed result, i.e. response (y), is described as a 
function of the controlled variables, i.e. factors (x1,x2…xj). The noise is left in the 
residual (). 
y = f(x1,x2…xj) +      (4) 
For practical purposes the function f can usually be approximated by using 
polynomial functions, since they give sufficiently good description of the relationship 
between factors and responses within a limited experimental domain. It should be 
noted that this type of models are local and cannot necessarily be extrapolated.
The idea behind DoE is to set up a design, in which all studied factors are varied 
systematically.107 Two level factorial designs form the basis for classical experimental 
designs. Here each factor is investigated at two levels: a low level and a high level. 
For continuous variables (e.g. temperature) this signifies two numerical values, but 
for discrete variables (e.g. type of instrument) this signifies two different alternatives. 
In a full factorial design all possible settings of the factors (i.e. low/high 
combinations) are included and with N factors the number of experiments will be 2N. 
Geometrical presentations of full factorial designs for two (22) and three (23) factors 
are shown in Figure 18. 
In a fractional factorial design only a selection of all possible combinations is 
executed. This reduces the number of experiments and is especially useful when 
screening many factors. In optimization, however, more experiments are needed to be 
able to calculate a model with higher terms. Central composite designs can be 
employed for this purpose. It is always recommended to perform replicated 
experiments at some factor settings; this will give an estimate of experimental error.  
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Figure 18. Examples of two level factorial designs for two (22) and three factors (23). 
Sign combinations in corner points show the levels (low -/ high +) used for each 
factor (xi) in that particular experiment. 
4.2.1 Multiple linear regression (MLR) 
In predictive modelling the objective is to determine the relationship between several 
x-variables (independent variables) and one or more y-variables (dependent variables) 
(see Eq. 4). For instance, a model with linear, interaction and quadratic terms for two 
x-variables can be written as: 
y = b0 + b1x1 + b2x2 + b12x1x2 + b11x12 + b22x22 +  (5) 
Where bi (i = 0, 1, 2,…) are regression coefficients describing the effect of each 
calculated term. Eq. 5 can be written in matrix form: 
y = Xb +         (6) 
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Parameters b can be estimated so that the sum of the squared residuals will be as 
small as possible, that is, we use least squares fit. MLR is often used for estimating 
regression vector b. From the Eq. 6 we get: 
b = (XTX)-1XTy    (7) 
The matrix XTX is always square but unfortunately it does not always have a full rank 
meaning that the usual inverse does not exist. The matrix (XTX)-1XT in Eq. 7 is then 
called a generalized inverse of X. 
Measured data are often collinear – variables are not independent and they contain the 
same information. MLR cannot be used in these situations. This is the reason why 
latent variable regression methods like partial least squares (PLS) have been 
developed. Instead of using strongly dependent variables in the regression we 
calculate a new set of (latent) variables that have a reduced dimensionality.  
4.3 Latent variable methods 
Characterization of complex chemical and biological systems produces multivariate, 
and in addition, collinear data, that is, variables describing partially or fully the same 
property and therefore sharing the same information content. Therefore, the original 
measured variables can be linearly combined to fewer, so-called latent variables, 
which describe the underlying structure in the data. In modelling the aim is to separate 
information from noise and find the patterns in the data. The concept of latent 
variables was first applied in psychometrics.108 This section provides a short 
description of latent variable methods used in this thesis. The methods are otherwise 
well described in the literature. 
4.3.1 Latent variable projections 
Each matrix can be geometrically presented in two co-existing spaces, variable space 
and object space, which together contain all available information in a data matrix 
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(Figure 19).109 Each object (sample) is described by N measured variables thus 
forming an object vector, xiT. Object vectors can be arranged in a matrix X, where 
each row represents one object. In the same manner, each variable is described by its 
values for all the M objects, that is, a variable vector, xj. When variable vectors are 
arranged in a matrix X, each column represents one variable. To visualize the data 
structure, object vectors can be plotted in variable space, where the number of axes is 
equal to the number of variables. In this way all the information in X regarding the 
relationships (similarities or differences) between objects can be displayed. Similarly, 
variable vectors can be plotted in object space, where the number of axes is equal to 
the number of objects. In this way the relationships (correlations/covariances) 
between variables can be shown. Since the object space shows common variation in a 
set of variables it also reveals underlying factors, that is, latent variables (LV). When 
the number of variables increases, the challenge is to find low-dimensional 
projections of both variable and object space. This can be achieved by projecting onto 
LVs. Different projections can be calculated using a generalization of NIPALS 
algorithm (Box 1).110 
 
Box 1. Successive orthogonal projections
i)    Select wa
ii)   Project objects on wa:
ta = Xawa
iii)  Project variable vectors on ta:
paT = taTXa/taTta
iv)  Remove the latent-variable from predictor space,
i.e. substitute Xa with Xa - tapaT.
Repeat i) - iv) for a= 1,2,..A,  where A is the dimension 
of the model  
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Figure 19. The two alternative ways to look at a data matrix X and the principle of 
latent variable (LV) projections.111 Three vectors, wa, ta, and pa, are needed to define 
the LV in the two spaces (see algorithm in Figure 20). Axes or vectors related to 
objects and variables are labelled with ‘o’ and ‘v’, respectively. In order to have a 
simple illustration, only three objects characterized by two variables are used. 
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The score vector ta and the loading vector pa are two different presentations of the 
LV, in variable space and object space, respectively (Figure 19). The selection of wa 
defines the LV uniquely and any LV method can be explained in terms of the 
selection of wa (Box 2). Several criteria can be used for decomposition of multivariate 
matrices to determine the axes for projections (Box 3).  
 
Box 2. Method overview
PCA/SVD           wa = pa/||pa||
PLS-DA              wa = yaTXa/|| yaTXa ||
TP                       wa = b/||b||
PCA, principal component analysis; SVD, singular value 
decomposition; PLS-DA, partial least squares discriminant
analysis; TP, target projection  
Box 3. Decomposition criteria
PCA  Maximum variance
PLS  Relevant components
TP  “Real” factors  
 
4.3.2 Principal component analysis (PCA) 
The most common latent variable projection method is principal component analysis 
(PCA).112, 113 The data matrix X is decomposed into a number of principal 
components (PCs) that maximize explained variance in the data on each successive 
component. The result is a bilinear model, a product of scores T and loadings P 
matrices: 
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X is an M × N matrix, consisting of M samples (rows) with N measured variables 
(columns). T is an M × A matrix and PT is an A × N matrix, where A is the number of 
calculated PCs. T and P consist of orthogonal and orthonormal vectors, respectively. 
E is an M × N matrix containing the residuals, that is, variance not explained by the 
PCs. Eq. 8 also shows the alternative description of the latent variable decomposition 
of X as a sum of products of score ta and loading pa vectors; a = 1, 2, … , A. The part 
of X explained by a pair of score and loading vectors in each step is removed before 
the next pair is calculated.  
PCA is a valuable data visualization technique. Since each object gets a score value 
on each PC, objects can be presented in a score plot. Score plot can reveal patterns, 
such as clusters, trends and outliers, in the data. In the same manner can variables be 
presented in a loading plot, since each variable gets a loading value on each PC. 
Loading plot reveals covariance among variables and can be used to interpret findings 
in score plot.  
Together scores and loadings map the structure in the data. The objective is to extract 
as many PCs as needed to explain the variation in the data; noise should be left in the 
residuals. Maximum number of components is equal to min [M,N]. 
4.3.3 Partial least squares (PLS) regression and PLS-discriminant 
analysis (PLS-DA) 
One of the most common objectives in data analysis is to calculate a model which 
shows how one or several responses (dependent variables), Y, can be explained by 
means of predictor variables, X. If the number of the X-variables is low and the 
variables are linearly independent (as in a case of designed experiments, see Section 
4.2) MLR works well. In most cases, however, there are many measured X-variables 
and they are not independent but correlated and noisy. This is always the case when 
working with spectral profiles. PLS regression is a modelling technique that takes into 
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account collinearity in the data.114-116 Instead of using strongly dependent X-variables 
we calculate a new set of LVs that have a reduced dimensionality.  
PLS decomposition can still be written similarly to PCA (see Eq. 8) but only the score 
vectors are orthogonal. The loading vectors are neither orthogonal nor of unit length. 
A normalized weighting vector w for PLS is calculated as the covariance between the 
response y and the data matrix X: 
XyXyw TTT
PLS,1
=    (9) 
Scores and loadings for the PLS components are calculated successively by projecting 
the spectral variables X on wPLS,1 and by projecting X on the resulting score vectors. 
Each step is checked for predictive power by using cross validation.117-119 The part of 
X explained by a pair of score and loading vectors in each step is removed before the 
next pair is calculated. 
PLS regression can also be used as a supervised classification method (see section 
4.3.4). The response variable is then a binary vector of zeros and ones, giving a class 
membership for each sample in the investigated groups. The method is called PLS-
discriminant analysis (PLS-DA).120  
4.3.4 Target projection (TP) 
The PLS model can be used to predict the response from X-variables like spectral 
profiles. Unfortunately, numerous PLS components are usually needed to describe the 
variation in X. This makes interpretation of PLS models difficult since the 
information about the response is scattered between the PLS components. The TP 
method offers a remedy for this problem.111 With TP, the information in the X-
variables orthogonal to the response variable is removed and a single latent variable 
(the target-projected component) is obtained that represents the direction in the 
multivariate predictive space with strongest relation to the response. TP represents the 
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optimal way of rotating a latent variable decomposition to a known target vector 
(response variable). 
The regression vector b, obtained from the PLS model, defines the direction in space 
with strongest relation to the response. Target-projected scores tTP, proportional to the 
predicted response, are obtained by projecting data matrix X onto the normalized 
regression vector wTP= b/||b||.  
bXbt =TP     (10)
TP loadings pTP can then be calculated as: 
( )TPTTPTPTTP tttXp =    (11) 
The TP loadings represent the features in the X-variables explaining and predicting 
the response variable. But they should not be directly used for feature selection (see 
Section 4.4). 
After target projection the PLS model is reduced to a single-component TP model: 
TP
T
TPTPTPTP
ˆ EptEXX +=+=  (12) 
With the same number of PLS components, the target-projected component is 
identical to the predictive orthogonal PLS component obtained from orthogonal PLS 
(O-PLS).121 TP and O-PLS thus represent different algorithms to achieve the same 
goal.122
A detailed analysis of interpretation of partial least squares regression models by 
means of TP method can be found in a recent paper by Kvalheim.123
4.3.5 Supervised classification using latent variables 
In supervised classification we know beforehand in which class each sample belongs 
to. For binary classification a response vector is created and values 1 or 0 are assigned 
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to the response according to the class membership of the samples. When new samples 
are measured and predicted using a PLS-DA/TP model response values close to 1 or 0 
should be obtained. The four possible outcomes of such a binary classification, that is, 
true positive, false positive, false negative, and true negative, can be formulated in a 
2×2 contingency table (Figure 20). If the classes have approximately the same size, 
the threshold in between (i.e. 0.5) can be used to decide the class membership for the 
tested samples. The threshold can of course be varied from case to case since the 
optimal choice is problem dependent. Balancing false positives against false negatives 
is used as criterion for deciding the threshold.  
In multiclass problems two strategies are possible: either a single model, including all 
groups, or several binary models, modelling the groups pairwise. The combination 
PLS-DA/TP is optimal with respect to finding the most discriminatory vector for a 
binary classification problem. PLS-DA/TP can be extended to handle more than two 
groups, but the classification result can no longer be presented on a single vector for 
feature selection. When doing several distinct classifications, we obtain the best 
discriminatory features for each comparison and if one then compares the results from 
all classifications, the features that provide separation of all groups simultaneously 
can be obtained. 
 
TNFNB (0)
FPTPA (1)
B (0)A (1)
Class
(true)  
Class
(predicted)
 
Figure 20. The four outcomes of binary classification can be formulated in a 2×2 
contingency table (confusion matrix). True positive (TP), false positive (FP), false 
negative (FN) and true negative (TN).  
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4.4 Variable/feature selection 
The number of objects is very small compared to the number of variables when full 
spectral profiles are acquired (i.e. tables are “short and fat”). This is a typical feature 
for all “omics” data. However, most of the variables are actually irrelevant as they 
represent variation not related to the response. Therefore the number of variables can 
be reduced drastically with minor loss of information. The challenge is to find the 
most significant variables. Variable selection methods aim at selecting a smaller panel 
of variables that are related to the response variable and thus needed for a good 
predictive model. When a large number of variables is measured it is impossible to 
test all the variable combinations in question; for instance, there are 2.46×1020
(500!/(490!10!) possible combinations to pick 10 variables out of 500. Variable 
selection methods are therefore needed to search for the best combination. 
Univariate variable selection methods treat each variable (e.g. peaks in a spectral 
profile) independently. Statistical values are calculated for each variable after testing 
differences between profiles from two sample groups. T-statistics and analysis of 
variance (ANOVA) are methods often used for this purpose. However, these methods 
do not take into account collinearity in the data and they cannot handle properly the 
situation with only a few samples compared to many measured variables. It is 
relatively easy to find a solution by pure chance and an irrelevant model will be 
created. In addition the use of traditional statistical tests assumes that the data obey 
normal distribution, which is typically not the case in real “omics” data.16 Due to 
small sample size and group heterogeneity, data in proteomic applications can not be 
assumed to follow a normal distribution. For these reasons t-test is not used in this 
thesis. 
Several multivariate variable or feature selection methods are available based on, for 
example, the covariances between the response and each variable (i.e. PLS weights), 
regression coefficients, variable importance on projection (VIP), interval PLS, and 
genetic algorithm.124-128 Wiklund et al. published recently the so-called S-plot.129 S-
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plot is a scatter plot showing covariance and correlation between the scores for the 
predictive O-PLS component and the spectral variables. Potential biomarker 
candidates should have both high covariance and high correlation to the score on the 
predictive component. The S-plot can be difficult to interpret since huge number of 
spectral variables makes it easily very crowded.  
Unfortunately most of these methods will usually lead to detection of false biomarkers 
since they are not specific enough to select the correct variables in complex spectral 
profiles. In this thesis two new tools for feature selection are developed. The main 
tool for searching for biomarker signatures is called selectivity ratio (SR). Its 
statistical significance can be determined using non-parametric test called 
discriminating variable (DIVA) test. 
4.4.1 Selectivity ratio (SR)  
The variable loading vector can be misleading for selecting the regions in the spectra 
corresponding to potential biomarkers. Since the PLS/TP model is estimated from 
covariances between the X-variables and the response, spectral regions that 
correspond to compounds with relatively large concentration may dominate the TP 
loadings even if the correlation with the response itself is low.  
The so-called SR plot was developed to solve this problem. SR is closely connected to 
the ratio of inter- to intragroup variation (see Section 5.2) and it is a measure of 
variable’s performance to separate groups. SR can reveal regions in spectral profiles 
with both high explanatory and high predictive significance for the investigated 
response.  
Explained vexpl,j and residual (unexplained) vres,j variance for each variable j in the TP 
model can be calculated from Eq. 12. The ratio between explained and residual 
variance defines a selectivity ratio SR for each variable:  
jres,jexpl,j vvSR =     j = 1,2,3… (13) 
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When calculated for spectral variables, SR can be displayed similarly to a spectrum 
(Figure 21). A high SR value means that the variable in question has a strong 
(predictive) correlation to the response, that is, the variable is highly selective. Thus, 
SR provides a quantitative ranking of variables (e.g. spectral regions) according to the 
response variable (e.g. class membership). This property makes SR a useful tool for 
variable selection in general and especially in applications where the number of 
measured variables largely exceeds the number of samples. Furthermore, by 
multiplying the SR with the sign of the corresponding regression coefficient or TP 
loading, it is possible to see if a variable increases or decreases when two groups of 
samples are compared.  
When searching for biomarkers in complex profiles with hundreds of compounds, a 
boundary between significant and unimportant variables is needed. An SR threshold 
can be chosen by the user and it is always a compromise depending on an application. 
A lower SR threshold increases the risk of selecting false biomarker candidates (false 
positives), while a higher SR threshold increases the risk of loosing potential 
biomarkers (false negatives). A statistical test is therefore developed to balance 
between these alternative situations. 
Figure 21. Example of a selectivity ratio (SR) plot. The chosen SR limits are marked 
with horizontal lines. 
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4.4.2 Discriminating variable (DIVA) test  
Discriminatory ability of a variable is high if its explained variance on the TP 
component is significantly higher than its residual variance. This hypothesis can be 
tested using F-test. 
Fcalc = SRi > Fcrit = F(,N-2,N-3)  (14) 
This will, however, result in a quite strict assumption that SR below one does not give 
significant discriminatory ability. In addition, the spectral data usually do not obey 
normal distribution as assumed when traditional univariate statistical tests are applied. 
For these reasons, a non-parametric statistical test has been developed to provide 
statistical boundaries for the SR method and thus make the feature selection easier. 
This test is called DIVA test.  
In DIVA test a probability p is obtained directly from measuring how well variables 
manage to separate two groups of samples.  
( ) NTNTPpDIVA +=    (15) 
TP and TN represent true positive and true negative classifications, respectively. 
Together they represent all the correct results in binary classification (see Figure 20 in 
Section 4.3.5). N is number of samples. By ranking all the samples according to 
descending (or ascending) values on each variable separately and using the known 
class membership of each sample, the correct classification rate (CCR) can be 
calculated for all the variables. If a variable contributes to a perfect separation, that is, 
100% CCR, samples belonging to one group get low values while samples belonging 
to the other group get high values on that variable. A variable contributing to 
completely random classification corresponds to 50% CCR with equal number of 
samples in each group. 
Since SR is a measure of how well each variable contributes to separation of groups, 
increasing SR should also increase CCR. When CCR is calculated for all the 
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variables, suitable SR intervals are defined and mean correct classification rate 
(MCCR) and its standard deviation for the variables in each SR interval are 
calculated. When MCCR is plotted against SR for all the SR intervals, a DIVA plot is 
obtained (Figure 22). This plot enables an objective determination of probability 
based boundaries for the SR plot. The chosen probability level can be seen as a 
compromise to balance between inclusion of false biomarker candidates and loss of 
potential true biomarkers. 
A receiver operating characteristics (ROC) curve is a bivariate plot representing 
sensitivity, or true positives, versus (1 − specificity), or false positives, in a binary 
classification as the discrimination threshold is varied.24 In our approach CCR is 
identical to sensitivity in a binary classification, and MCCR can be interpreted as a 
mean sensitivity for the variables within a certain SR interval. DIVA plot connects 
variables’ classification performance to their ratio of inter- to intragroup variation and 
thus expands the ROC curve into a multifeature domain. ROC is described in full 
detail elsewhere.130  
Figure 22. Example of a discriminating variable (DIVA) plot mean correct 
classification rate (MCCR) and its standard deviation are plotted against selectivity 
ratio (SR). The chosen SR value is marked with vertical line.
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5. Summary of results 
“Everything should be made as simple as possible, but not simpler.” Albert Einstein 
The challenges discussed in earlier chapters are addressed in the four scientific papers 
for which this thesis is based on. This chapter presents a summary of these papers 
(denoted as Papers I-IV). 
5.1 Background information 
5.1.1 Study population and sampling 
Study population consisted of patients at Haukeland University Hospital. Clinical 
evaluation and diagnostic lumbar puncture of patients with MS and other neurological 
diseases (OND) were performed at the Department of Neurology. CSF from the 
neurological healthy controls (NHC) was collected from patients that received spinal 
anaesthesia for lower extremity orthopaedic surgery at the Department of Orthopaedic 
Surgery. Written informed consent was obtained from the included patients and the 
study was approved by the Regional Committee for Medical and Health Research 
Ethics and the Norwegian Social Science Data Services.  
CSF samples were taken by a standard lumbar puncture procedure. Few millilitres of 
CSF were immediately placed on ice and centrifuged at 450 x g for 10 minutes to 
remove cells, before freezing at -80 °C.  
5.1.2 Sample preparation and instrumentation 
Samples were fractionated using MW cut-off filters. The filter removed the most 
abundant proteins above a chosen threshold: 20 kDa (Paper I) and 30 kDa (Papers II-
IV).  
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In MALDI-TOF analyses two matrices, -cyano-4-hydroxycinnamic acid (CHCA) 
and 2,5-dihydroxybenzoic acid (DHB), were used. The low MW fraction was spotted 
onto a 600 µm AnchorChip® (using CHCA matrix) and the guanidinium fraction was 
spotted onto a steel target plate (using CHCA+DHB mix 1:1).  
All the samples were analyzed using AutoFlex (Bruker Daltonics) MALDI-TOF mass 
spectrometer. The instrument was operated using nitrogen laser at 337 nm in 
ionization (laser frequency 20 Hz, ion source I 20 kV) and a positive linear mode in 
mass analysis. Data were acquired in two different ranges: 740-9000 Da defined as a 
low mass range (low MW fraction), and 6000-17500 Da defined as a medium mass 
range (guanidinium fraction).  
5.1.3 Data sets 
Paper I 
Data set 1: Spiked sample  
A CSF pool was created by mixing CSF from five different neurological patients. Six 
samples were prepared from the CSF pool: three of them were spiked with 1600 pM 
peptide standard (Table 3) and three were kept as reference samples. All the samples 
were fractionated and the low MW fraction was analyzed in triplicates. This provided 
a dataset of 18 spectral profiles, each described by 44 403 m/z values. Three profiles 
(representing one reference sample) were excluded from further study as outliers after 
visual inspection by PCA.  
Data set 2: Storage data 
Fresh CSF was obtained from a 30 years old male with some neurological symptoms. 
The sample was split into aliquots and stored under 15 different storage conditions29
thus resulting in 15 samples. All the 15 samples were fractionated to create a low MW 
fraction and a guanidinium fraction. The guanidinium fraction of the samples was 
analyzed in triplicates to provide 45 spectral profiles, each described by 16 598 m/z
values. 
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Table 3. Peptide and protein standards used for spiking of cerebrospinal fluid (CSF) 
samples.
Peptide standard Protein standard 
m/z  Name m/z Name 
1 047.20  Angiotensin II 5 734.56 Insulin 
1 297.51  Angiotensin I 8 565.89 Ubiquitin I 
1 348.66  Substance P 12 361.09 Cytochrome C 
1 620.88  Bombesin 6 181.05 Cytochrome C ((M+2H)2+)
2 094.46  ACTH clip 1-17 16 952.55 Myoglobin 
2 466.73  ACTH clip 18-39 8 476.77 Myoglobin ((M+2H)2+) 
3 149.61  Somatostatin 28   
Data set 3: Replicated sample 
A CSF pool was created by mixing CSF from ten different neurological patients. Five 
replicated samples were prepared from the CSF pool. The samples were fractionated 
and the low MW fraction was analyzed in triplicates. A data set of 15 spectral profiles 
was acquired, with each profile described by 44 403 m/z values. 
Paper II 
A CSF pool was created by mixing CSF from several neurological patients. The pool 
was divided into four samples (i.e. SP0, SP1, SP2 and SP3). Sample SP0 served as a 
reference sample. The other samples were spiked with the following concentrations of 
peptide and protein standards (Table 3): 400 pM / 2 nM (SP1), 800 pM / 10 nM (SP2) 
and 1600 pM / 40 nM (SP3). Three replicates for each sample were prepared and 
fractionated. Both fractions, the low MW fraction and the guanidinium fraction, were 
analyzed in triplicates thus resulting in 9 replicated spectra for each fraction of the 
four samples (i.e. 36 spectra per fraction). The peptide calibration standard should 
73
only appear in the low MW fraction (data set 1) and the protein calibration standard 
should only appear in the guanidinium fraction (data set 2).  
Paper III 
CSF samples were drawn from NHC and randomly partitioned into five groups. One 
group, labelled 0 pM, was selected as reference. CSF from the other four groups was 
spiked with 50, 100, 200, or 400 pM of peptide standard (Table 3). Samples were 
fractionated in duplicates and the low MW fraction was analyzed in triplicates. Some 
profiles were excluded from further study as outliers after visual inspection by PCA. 
This provided a data set consisting of approximately 170 reference spectra and 
approximately 50 spectra for each of the spiked samples. Each spectrum is described 
by 44 403 m/z values. 
Paper IV 
CSF samples from patients with MS, OND and NHC, 18 in each group, were 
included (Table 4). Samples were fractionated and the low MW fraction was 
analyzed. Number of replicates varied between samples. In total there were 498 
profiles, each described by 44 403 m/z values. 
Table 4. Study population in Paper IV; patients with relapsing-remitting multiple 
sclerosis (RRMS), other neurological diseases (OND) and neurological healthy 
controls (NHC).
Group No of 
patients 
Females Age range 
(years) 
Males Age range 
(years) 
MS 18 15 22-73 3 30-58 
OND 18 10 27-71 8 48-79 
NHC 18 9 33-83 9 19-80 
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5.1.4 Software 
MALDI-TOF sampling and preanalysis, including baseline correction, was performed 
using instrument’s own FlexAnalysis software (Bruker Daltonics). SpecAlign version 
2.3 (Cartwright Group PTCL, University of Oxford) was used for peak alignment in 
Paper I.100 MATLAB version 6.5 (Mathworks Inc.) was used for calculation of the 
response R in Paper I. All additional chemometric analyses were programmed in 
Sirius software package from Pattern Recognition Systems AS (versions 7.0 and 8.0). 
5.2 Pretreatment of mass spectral profiles (Paper I) 
This study provided a recommended workflow on how to pretreat the spectral data 
prior to multivariate analysis. An optimal data pretreatment consist of steps that 
eliminate differences in profiles resulting from experimental and instrumental factors, 
but at the same time preserve the compositional information. Theoretical 
considerations of data pretreatment are presented in Section 4.1.  
Factorial experimental designs, with different pretreatment steps as design variables, 
were employed for deciding the optimal procedure. Use of design makes it possible to 
evaluate the relative importance of the different steps and, in addition, their 
interactions since these may be expected. The investigated pretreatment steps were 
binning/smoothing, alignment, structured noise, and normalization. The response 
variable was the ratio of inter- to intragroup variation, R, that is, the variation between 
groups of samples was compared to the variation within replicated samples. 
Successful data pretreatment enhances the information content in the spectral profiles 
meaning that the ratio R increases. 24 designs were executed for three different sample 
sets (described in detail in Section 5.1.3) thus resulting in three different models. The 
most important factors and their contributions were identified from the coefficients 
provided by MLR. Theoretical aspects of DoE and empirical modelling are presented 
in Section 4.2. 
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The spectral profiles were baseline corrected using the instrument vendor’s software 
(FlexAnalysis). Since this produced regions with negative intensities, the profiles 
were independently adjusted by the absolute value of the largest negative intensity so 
that the lowest intensity became zero. For spectral alignment, the SpecAlign software 
was used. For smoothing a moving average with a 10-point window and for binning a 
10-point window was used. Several transformations to eliminate structured noise 
were tested and square and third root transformations were found to be appropriate. 
Normalization was performed using unit length (norm). 
In data sets 1 and 2, a separation between different groups was expected and therefore 
the variation between groups should be larger than the variation within a group (i.e.
maximize R). In data set 3, all profiles represented the same replicated sample and no 
separation was expected. Thus the optimal data pretreatment should remove the 
undesired effects without increasing R. 
The results showed that the tested pretreatment steps had significant interactions and 
therefore they should not be interpreted solely based on their main effects. Strong 
interactions were observed especially between structured noise and normalization, 
and normalization and alignment as shown by regression coefficients (Figure 23). 
Normalization was undoubtedly the most important factor in all three cases. However, 
heteroscedastic noise should always be transformed to homoscedastic noise prior to 
normalization. Otherwise there might be a risk of false biomarker discovery. Use of 
nth root transformation, with n equal to two or three, is recommended. Log 
transformation is too rough and it also destroys linear correlations in the profiles. 
Alignment was necessary in most cases and should be performed routinely. No 
difference between smoothing and binning was observed. Binning reduces the 
number of data points and speeds up the data analysis. It was shown that even 
reduction with one order of magnitude can be done without loss of information. In 
addition, use of binning made smoothing unnecessary, since binning acts as a filter. 
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Figure 23. Regression coefficients and their confidence intervals for data sets 1-3. 
Positive bar means that the ratio of inter- to intragroup variation, R, is increasing 
and negative bar means that R is decreasing when changing a variable from -1 to +1 
level. For data sets 1 and 2, increasing R implies that profiles within a group become 
more similar without destroying the compositional correlation pattern. For data set 3, 
the undesired effects should be removed without increasing R, since this is a 
replicated sample and no separation should be observed.
The analysis also demonstrated the need for replicated analysis; both to be able to 
reduce heteroscedastic noise, and to assess experimental errors. 
The recommended order of pretreatment steps was as follows: smoothing/binning, 
alignment, transformation of structured noise and normalization. The pretreatment 
scheme was applied to further work in Papers II-IV (Figure 24). 
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Figure 24. Pretreatment scheme used in Papers II-IV. Specifications for different 
steps are: smoothing using moving average with window size 10, binning with 
window size 5, alignment using recursive alignment by fast Fourier transform 
(RAFFT) with window size 20, transformation using square root, and normalization 
using unit length. Negative intensities were corrected by either assigning zero to the 
lowest signal in each profile independently (Papers II and III) or setting such 
intensities to zero (Paper IV). 
5.3 Variable selection using selectivity ratio (SR) (Paper II) 
A new method for variable selection in complex spectral profiles was presented in 
this study. The method uses so-called selectivity ratios (SR) and it is based on TP 
modelling. The SR for all the spectral variables on the target-projected component is 
obtained by calculating the ratio between explained variance and residual variance. 
The SR plot is a quantitative display of all the SRs showing all important features for 
interpreting the target component and ranking the discriminating variables (e.g. 
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biomarkers). Variables with a high SR value have a good discriminatory ability and 
are therefore contributing most to the separation between different groups. The theory 
of SR is presented in detail in Section 4.4.1.  
The method was validated using two data sets (described in detail in Section 5.1.3) 
consisting of pooled CSF samples spiked with known concentrations of peptide and 
protein standards. The acquired MALDI profiles were pretreated prior to data analysis 
according to the scheme presented in Figure 24. Three binary classification models 
(i.e. reference samples SP0 versus spiked samples SP1, SP2 and SP3) were then 
created using a combination of PLS-DA and TP modelling. A binary response 
variable, giving the class membership of the samples, got values 0 and 1 for the 
reference samples and spiked samples, respectively. SR threshold was chosen by 
visual inspection; here SR value 3 was used, that is, at least 75% of the original 
variance was explained by the selected variables. 
Spiking imitates the pathogenesis of a disease where abundances of certain proteins 
increase over a period of time. The results showed that in the low MW range (740-
9000 Da) it was possible to detect spiked peptides at least down to 400 pM level using 
SR method without severe problems with false biomarker candidates. At this level we 
were able to detect six of the seven added peptides in the spiked sample (Figure 25). 
Three false candidates were also detected with SR values just above the chosen SR 
limit. With higher concentrations the detection became less vulnerable to false 
candidates. In the medium mass range (6000-17500 Da) it was possible to detect 
spiked proteins at least down to 2 nM level. At this level only two of the six added 
proteins were detected. However, it was possible to classify the samples correctly in 
both data sets using the selected m/z regions, meaning that the diagnostic power of the 
reduced profiles (i.e. biomarker signature) was high. 
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Figure 25. Selectivity ratio (SR) plot for low mass range (740-9000 Da) for the 
reference samples (SP0) versus spiked samples (SP1) classification. The chosen SR
threshold is marked with horizontal line.  
Comparison with some commonly used tools for variable selection (e.g. X-weights, 
regression coefficients, and VIP) showed that SR had the best performance (Figure 
26). This is probably due to the fact that target projection utilizes both the predictive 
ability (regression coefficients) and the explanatory ability (spectral 
variance/covariance matrix) for the calculation of the SR. 
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Figure 26. Comparison between different variable selection methods applied to 
spectral profiles in low mass range. From the top: Covariances between spectral 
variables and group membership (i.e. X-weights, w), regression coefficients, variable 
importance on projection (VIP), and selectivity ratio (SR) plot. 
5.4 Discriminating variable (DIVA) test for defining 
probability based boundaries for the SR plot (Paper III) 
In this study the SR method was further improved by introducing a nonparametric 
discriminating variable (DIVA) test to obtain probability based boundaries for the SR 
plot. Furthermore, interpretability of the SR plot was enhanced by multiplying each 
SR value with the sign of the corresponding regression coefficient (or TP loading as 
in Paper IV). Introduction of signs to SR plot makes it possible to see which variables 
are more and less abundant when comparing different groups. The combination of SR 
plot and DIVA test provides an objective and quantitative tool for variable selection 
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in complex spectral profiles. The theory of DIVA is presented in detail in Section 
4.4.2. 
The improved SR plot combined with DIVA test was validated using a data set 
(described in detail in Section 5.1.3) consisting of CSF samples spiked with known 
concentrations of peptide standard. Samples were not pooled but used separately, thus 
giving a more realistic imitation of a real diagnostic situation where patient to patient 
variation is present. The acquired MALDI profiles were pretreated according to the 
scheme presented in Figure 24. In this study binning (window size 5) was used 
instead of smoothing. This reduced the number of variables from 44 403 to 8 881 m/z
numbers. Four binary classification models (i.e. reference samples 0 pM versus 
spiked samples 50, 100, 200 and 400 pM) were then created using a combination of 
PLS-DA and TP modelling. A binary response variable, giving the class membership 
of the samples, got values 0 and 1 for the reference samples and spiked samples, 
respectively.  
An SR threshold was chosen with the help of DIVA test. DIVA plot (Figure 27) 
shows MCCR plotted against SR. It was obtained by first calculating the SR and the 
percent CCR for all the binned m/z numbers. Variables were then sorted according to 
their SR values and MCCR and its standard deviation were calculated for specified 
SR intervals. In 0 pM vs. 100 pM classification the SR threshold of 0.5 
(corresponding to approx. 80% MCCR) was chosen. The results showed that at the 
concentration level 100 pM, three of the seven added peptides were visible above the 
threshold (Figure 28). However, an excellent separation between the sample groups 
was obtained with PCA when using only the selected m/z regions (less than 0.3% of 
the original profiles). This demonstrates again the high diagnostic power of this 
methodology.  
The results were very similar for the three other classifications as well. However, for 
the lowest concentration (50 pM) one of these three peptides was under the chosen SR 
threshold. This resulted from depletion due to smaller and smaller amounts of peptide 
standard. 
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Figure 27. Discriminating variables (DIVA) plot for the 0 pM versus 100 pM 
classification. 
Figure 28. Selectivity ratio (SR) plot for the 0 pM versus 100 pM classification. 
Comparison with other methods showed that our approach had the best performance 
providing only correct candidates (Figure 29). 
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Figure 29. Comparison between different variable selection methods applied to 
spectral profiles in low mass range. From the top: Covariances between spectral 
variables and group membership (i.e. X-weights, w), regression coefficients, variable 
importance on projection (VIP), and selectivity ratio (SR) plot. 
5.5 Application: Biomarker signatures for disease 
classification (Paper IV) 
In this work the low MW fraction of the CSF proteome of samples from patients with 
MS, OND and NHC (described in detail in Section 5.1.3) was characterized using 
MALDI-TOF spectral profiling. Our novel targeted multivariate approach was 
applied to the profiles to reveal the features distinguishing different groups. The 
detected biomarker signature was then used for disease classification. The complete 
workflow is shown in Figure 30. This is the first application of the developed 
methodology to the analysis of real proteomics data. The approach is general and can 
be applied for other diseases and instrumental techniques as well. 
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Figure 30. Workflow used in Paper IV. 
 
The acquired MALDI profiles were pretreated according to the scheme presented in 
Figure 24. Three binary classification models (i.e. MS vs OND, MS vs NHC, and 
OND vs NHC) were created using a combination of PLS-DA and TP modelling. A 
binary response variable, giving the class membership of the samples, got value 0 for 
all the NHC samples and 1 for all the MS samples. OND samples got the value 0 in 
MS vs OND classification and 1 in OND vs NHC classification. An appropriate SR 
threshold was chosen with the help of DIVA test for each classification separately; 
the value varied between 0.5 and 0.6. 
Several discriminating spectral regions were found using this approach. The selected 
m/z regions corresponded to 0.2-1.8% of the original spectral profiles. These regions 
were not necessarily whole peaks but fractions of them. The most interesting regions 
were those common to several classifications; we observed eight m/z regions that 
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were common to two subset classifications. Two of the regions were relatively more 
abundant in MS patients (around m/z 2299 and 2498). Four regions were relatively 
more abundant in patients with neurological diseases, that is, MS and OND (around 
m/z 2430, 3237, 5121, and 7162) while two regions were less abundant in the samples 
with neurological diseases (around m/z 2318 and 2821).  
Despite the huge reduction in spectral variables, the loss of information in the 
classification pattern was surprisingly small. In binary classification excellent 
separation between the two groups in each subset was observed (Figure 31).  
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Figure 31. Scores on the target-projected (TP) component for the detected biomarker 
signatures in classifications (A) MS vs. OND, (B) MS vs. NHC, and (C) OND vs. 
NHC. MS (red), OND (blue) and NHC (black).   
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A few of the replicated spectra from some samples comparing MS vs. OND and OND 
vs. NHC were falsely classified. In MS vs. OND classification only one MS and one 
OND patient were falsely classified when taking into account the replicate variation 
in the samples. In OND vs. NHC classification only one NHC patient was 
systematically falsely classified. The separation of MS from NHC was perfect after 
variable reduction. 
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6. Conclusions and future perspectives 
“By three methods we may learn wisdom: First, by reflection, which is noblest; 
second, by imitation, which is easiest; and third by experience, which is the bitterest.” 
Confucius  
This thesis has discussed the detection of biomarker signatures using mass spectral 
profiling and multivariate analysis. The main results of the thesis can be summarized 
as follows: 
1. Traditional way to analyze spectral profiles is to reduce the full profiles to peaks. 
Doing this, however, may also reduce the information content in the data. In addition, 
most of the problems encountered using full spectral profiles are also valid for a peak 
based approach. Data pretreatment is needed to eliminate non-compositional features 
from the spectral profiles without destroying the compositional differences. The 
problem with heteroscedastic noise is an example of this dilemma. Heteroscedastic 
noise can be transformed to homoscedastic noise using the nth-root transformation, but 
this transformation impacts the correlation between variables. On the other hand, it 
provides better opportunities for variables with low concentrations to be detected in 
the biomarker discovery process.  According to our experience a choice of n equal to 
two is reasonably robust, but this can be verified by comparing replicates after the 
transformation. Strong interactions exist between different pretreatment steps. 
Normalization of the mass spectral profiles without prior transformation of structured 
noise may give rise to false biomarker candidates. Replicated analyses are always 
recommended; both to be able to reduce heteroscedastic noise, and, to assess 
experimental errors.  
2. Several methods exist for feature selection but most of them have not given 
satisfying results when applied to biomarker detection. Univariate methods, such as t-
test and ANOVA, should not be used when data are highly collinear and not normally 
distributed. In addition, it is relatively easy to find biomarkers by pure chance when 
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the number of variables is high compared to the number of samples. Multivariate 
methods are mainly based on looking at variable loadings or regression coefficients. 
They will usually lead to detection of false biomarkers since these methods are biased 
towards selection of variables with large variance. In this thesis a new feature 
selection tool called selectivity ratio (SR) plot is developed. The SR plot shows 
quantitatively all important features present in profiles needed for interpretation of the 
target component, and thus makes an objective selection of discriminating variables 
possible. Accompanied with a new nonparametric discriminating variable (DIVA) 
test, to obtain probability based boundaries for SR, the method is shown to 
outperform currently available graphical tools for feature selection. This method can 
be utilized in all multivariate methods providing a single predictive component for 
each y-variable.  
3. The combination of PLS-DA and TP modelling of spectral profiles, followed by 
feature selection with SR plot and DIVA test, provides a workflow for detecting 
biomarker signatures from complex spectral profiles. With this approach both narrow 
and broad discriminatory m/z regions are located without the need for the assumption 
that variables must represent whole single separated peaks. These regions can be 
combined into disease patterns with the best possible performance with respect to 
separating groups from each other. Furthermore, these disease patterns provide the 
most promising m/z regions for biomarker discovery in the investigated fraction. 
These features of our approach represent an advantage over the conventional peak 
based methods. 
Future perspectives 
In this study we have developed new methods to reveal m/z regions with 
discriminating ability and thus a pattern serving as a potential biomarker signature. 
Follow-up analysis is necessary to provide the identification of the candidate 
biomarkers. Multivariate resolution techniques can for example be used to separate 
overlapping peaks. These techniques are time-consuming and not easy to automate, 
since they need more expertise and interference from the operator. A better approach 
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is therefore to use other mass spectroscopic techniques that can utilize the information 
already obtained about promising m/z regions.   
Although only used on MALDI-TOF spectral profiles in the present work, our data-
analytical approach is much more general. The generalization to surface-enhanced 
laser desorption/ionization (SELDI) mass spectrometry and nuclear magnetic 
resonance (NMR) spectroscopy data is obvious, but by using the technique of 
unfolding, also data from hyphenated instruments like liquid chromatography-mass 
spectrometry (LC-MS) can be analyzed by our approach. 
The combination of SR plot and DIVA test represents a variable selection method that 
can be applied to all data analytical problems with many correlated variables and 
complex patterns. For example, gene expression data and metabolomic data can be 
analysed using this approach. 
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